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 INTRODUCTION 
 
            Breast cancer is a multifactorial disease which is having distinct biological 
subtypes. They have a broad spectrum of clinical, pathological and molecular 
characteristics resulting in different prognostic and therapeutic applications. 
Therefore, every lump in the breast should be considered as a malignant lesion 
until proved otherwise.  
           As breast is one of the frequent sites which is under the influence of 
hormones, major hormonal changes during adolescent period, child bearing period 
and at the time of menopause will affect the mammary tissue. Breast cancer is one 
among the frequently encountered malignancies in the world among females. 
There should be enough knowledge about its epidemiology at the regional as well 
as in worldwide basis and this will provide a way for its effective control. 
         Many of the Indian literature report that the age incidence of breast cancer in 
the Indian females is somewhat prior to the western population. Among urban 
females, carcinoma breast has come up as the leading cause of cancer-related 
mortality6 and has overtaken carcinoma cervix. With the knowledge of complexity 
and heterogeneity of breast cancers, intensive efforts have been undertaken to 
study the correlation between clinical characteristics and the histopathological as 
well as molecular features. Also, there is a steady and persistent work up in 
identifying certain predictive factors to deal with the disease prognosis and 
treatment strategy.  
         In low and middle income countries, Breast cancer related mortality has been 
in the range of 55% of all new cases per year (Curado et al, 2007).  In India the 
incidence of breast cancer constitutes about one third to one fourth that in USA but 
still stands as the leading cause of cancer among women (Ferlay et al, 2004, Datta 
et al 2012). 
       Though the incidence is lower, the total number of cases and the mortality is 
high because of the population burden, insufficient screening facilities and lack of 
education. To reduce this increasing load of mortality, we need to consider the 
importance of early detection and the availability of systemic therapy and for this, 
we should have a better understanding of the trend, age group involved and other 
risk factors. 
       Even if, a great advancement has emerged in the management of breast cancer, 
the concept in the management of breast cancer is to bring forward an individual 
based treatment plan to avoid excessive and ineffective treatment that can cause 
unnecessary morbidity and mortality. Estrogen receptor (ER) which has been 
discovered in 196247 has become the first molecule with great effectiveness in the 
intervention of invasive Breast cancer.  
      Nowadays, breast carcinoma is considered as a distinct and exclusive disease in 
oncology and the specific biologic markers - ER, PR are utilised to predict the 
hormonal response and serve as a guide for the therapeutic plan.  Hormonal 
receptor positive and negative cases have different biological behaviour, distinct 
treatment protocol and prognostic implication. 
       This study aims at correlating the factors like age of the patient, clinical 
presentation, histological grade, stage and the hormonal receptor status with 
respect to menopausal status and different histological types of breast carcinomas. 
An attempt has been made to evaluate the various morphological patterns of the 
malignant lesions of the breast and their age distribution from the mastectomy 
specimens along with the axillary lymph node dissection in the Department of 
pathology, Madurai medical college, Madurai. 
        With the help of the hormonal receptor (ER, PR) assessment, the prognostic 
assessment and the treatment modality of breast cancer can be done with precision.  
 
 
AIM OF THE STUDY 
 
• To study the frequency of occurrence of malignant lesions in the 
mastectomy specimens received from Government Rajaji hospital, Madurai 
to the Department of pathology, Madurai Medical College, Madurai. 
 To find out the incidence of malignant lesions with regard to age, sex, 
laterality of the breast and menopause. 
 To study the histological types of breast carcinomas. 
 To determine the various prognostic parameters of breast carcinomas. 
 To determine the significance of histological grade among the breast 
carcinomas. 
 To demonstrate the hormone receptor status such as Estrogen and 
Progesterone receptor (ER, PR) in different age groups. 
 To analyse the hormone receptor status in relation to premenopausal and 
postmenopausal age group. 
 To find out the hormone receptor status in different histological types of 
breast carcinoma. 
REVIEW OF LITERATURE 
Although antiquity incorporates an overview of many decades, a few recent 
years are included to summarise achievements and failures. A historical evaluation 
conveys a hope for future improvements about the diagnosis and management of 
breast cancer.  
         Diseases of the breast have drawn attention of medical interest as long as 
3000 B.C. The Edwin smith of Egyptian pyramics age (3000 – 2500 B.C.) 
described many cases of breast cancer. In reality, breast carcinomas were the first 
human cancers discovered. The Egyptian surgeons emphasized that it was difficult 
to remedy hard lumps of the breast.47 
In 1656, Marcus Aurelins Saverinus was the first surgeon who removed the 
enlarged axillary lymph glands at the time of breast amputation. He advocated the 
excision of the benign tumours in the breast because of the increased relative risk 
of them becoming malignant. Leonides was the first to emphasize that nipple 
retraction is a significant clinical sign of breast malignancy47. In 1560, the relation 
of breast cancer to the axilla and its extension was documented by Ambroise Paire, 
a French army surgeon. 
 
DEVELOPMENT 
         The breast is a complex apocrine gla
in woman but becomes a rudimentary organ in males.
In the human embryo, the ectoderm bec
extends from the axilla to the inguinal region and this thickening
mammary ridges. From a part of this mammary line
develops that overlies the pectoral area at sixth week of 
Presumptive cords are
and grow into the underlying dermis. They 
the ductal structures. The terminal parts of cords
elements. During puberty and pregnancy, 
extensive development. Accessory breast which is observed in 1% of the females 
may be found in neck, cheeks, femoral triangle and vulva. 
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ANATOMY3: 
The structure of the breast consists of skin, parenchyma and stroma. The 
skin covers the gland and presents a conical projection called nipple at the level of 
fourth intercostal space. It contains circular and longitudinal smooth muscle fibres. 
The skin surrounding the base of the nipple is pigmented and forms areola which is 
rich in modified sweat glands. The parenchyma is composed of glandular tissue 
which secretes milk. The gl
alveoli, drained by lactiferous duct which has a dilatation at its termination called 
lactiferous sinus and open in to the nipple. The stroma is partly fibrous and partly 
fatty which anchors the skin a
and consists of 15-20 lobes. Each lobe is a cluster of 
nd gland to pectoral fascia. 
 
Vessels and Nerves:- 
The arteries arise from the axillary, the intercostals, and the internal 
mammary arteries. The veins form an anastomotic circle and end up in the axillary 
and internal mammary veins. The nerves arise from the lateral and anterior 
cutaneous branches of the fourth, fifth, and sixth thoracic nerves. Lymph from the 
breast drains in to axillary nodes, internal mammary nodes, supraclavicular and 
posterior intercostal nodes. 
HISTOLOGY4: 
Lobule is the functional unit of the breast. A lobule consist of numerous 
acini (glands) lined by two-layered epithelium. 
- Outer flattened myoepithelial cell, 
- Inner cuboidal or columnar cell. 
The acini drain its secretions into a terminal duct. Each terminal duct and its 
acini are together called as the Terminal Duct Lobular Unit (TDLU) which is 
thought to be the origin of breast tumours.The terminal duct ends in a sub-
segmental duct, segmental duct, and terminates into lactiferous duct. There are 15 
– 20 lactiferous ducts which terminate into the nipple. Immediately below the 
nipple, lactiferous sinus is formed by the dilatation of lactiferous duct.  
PHYSIOLOGICAL CHANGES
In accordance with the state of activity, t
In the gland of nulliparous woman
granular polyhedral cells. During pregnancy the alveoli enlar
During lactation, in the centre of the alveoli, the cells 
and are extruded in the first milk, as colostrum corpuscles. The peripheral cells of 
the alveoli remain as single 
flattened when the acini become
HORMONES ACTING ON BREAST
Breast development is 
progesterone. Estrogen causes proliferation of mammary ducts and progesterone 
causes growth of lobules and alveoli. During pregnancy the large amount of 
estrogen secreted by the placenta causes the duct
hormones like growth hormone, prolactin, adrenal glucocorticoids and insulin. 
 
4: 
he epithelium of the breast differs. 
, the alveoli are small and filled with a mass of 
ge and multiply. 
undergo fatty 
short columnar cells. The lining epithelium becomes 
 distended with secretion. 
42: 
stimulated by the hormones estrogen and 
al system to grow, with other 
degeneration, 
Oxytocin and prolactin are essential for milk secretion and ejection during 
lactation. 
INCIDENCE AND EPIDEMIOLOGY: 
       Carcinoma affects all the communities worldwide. Out of the 10 million 
people who are diagnosed with carcinoma, more than 6 million people die of 
cancer every year52. Breast carcinoma stood first among the malignancies in 
women. On a Worldwide basis, it causes 3,76,000 deaths per year and  9,00,000 
new cases are diagnosed every year.31 
      On accounting the prevalence in Indian women, carcinoma cervix and breast 
account for 60% of cases, of which the incidence of breast carcinoma is 10.4%. A 
study conducted by WHO31 (1999) documented that Chennai has the highest 
incidence among all the centres in India (ie) 26/1,00,000 women. The mean age for 
the incidence is 42 years53. 
 
Due to the widespread use of mammography,50 the detection of breast 
carcinoma has been increased. However, the mortality from breast carcinoma is 
somewhat reduced which may be because of improved therapy50. 
RISK FACTORS: 
The increased prevalence of the disease has given a way to the vigorous 
study about risk factors. Strong and prolonged estrogen stimulation with a 
genetically susceptible background has been documented as a common risk 
factor52, 44, 45. 
1. Place of birth: Incidence of breast cancer is common in developed countries than 
in developing countries. 
2. Family history: Females who have first degree relatives with breast cancer have 
a two to three times more risk that of the general population. 
3. Nulliparity: Unmarried women and nulliparous women have more risk for 
developing breast cancer. Also, late age at first pregnancy (30 years and above) has 
been documented as a risk factor. Multiparous women had 50% risk reduction in 
comparison with nulliparous females. 
4. Menstrual history: Increased risk is associated with early menarche and late 
menopause due to estrogenic stimulation.53 
5. Proliferative Breast disease: Increased risk is associated with prior biopsies of 
the breast showing fibrocystic disease (Fig 7) and atypical ductal hyperplasia 
(relative risk 4.0 – 5.0).53 
6. Socio economic group: Increased risk is associated with high socio- economic 
group. The risk of developing breast cancer within the next 20 years period at the 
age of 50 is 1 in 26 among Asian countries. 
Additional risk factors are also found out, but there is a lack of definitive 
relationship53. 
1. Estrogen exposure: Postmenopausal hormone replacement therapy and oral 
contraceptive drugs usage are affiliated with the risk of developing breast cancer. 
Oophorectomy reduces the risk of breast cancer by 75%. 
2. Carcinoma of contralateral breast and endometrium: Approximately 1% of 
females with breast cancer develop a breast cancer in the contralateral breast per 
year.53 
3. Radiation exposure: Those who are exposed to therapeutic radiation and atom 
bomb survivors are prone for development of breast cancer. 
4. Geographic influence: Breast cancer incidence rates are about four times 
increased in the United States and Europe than in other countries. 
5. Diet: High fat diet and obesity have increased risk. 
6. Breast feeding: The longer period of breast feeding is associated with reduction 
in the risk of breast carcinoma. 
7. Exercise: Risk is reduced in association with regular exercise. 
ETIOLOGY AND PATHOGENESIS53: 
The major risk factors for the genesis of breast cancers are hormonal and 
genetic (family history).  
Breast cancers can be divided into 
 1) Sporadic breast carcinoma. 
2) Hereditary breast carcinoma. 
HEREDITARY BREAST CARCINOMA: 
        About 25% familial breast cancers can be ascribed to two highly penetrant 
autosomal dominant genes BRCA 1 and BRCA 2, located in 17q21 and 13q12.3 
respectively. They function on similar pathways and interact with multi protein 
complexes. Both act as tumour suppressor genes and loss of function leads to 
breast carcinoma due to proliferation of breast epithelium. BRCA 1 interacts with 
estrogen receptor and is involved in X- Chromosome activation. 
        BRCA1mutations are more common in medullary carcinoma (67%) and 
mucinous carcinoma (55%), BRCA2 mutation does not have a definite 
morphologic appearance.52,64 
SPORADIC BREAST CARCINOMA: 
        The vital risk factors for sporadic breast cancer are attributed to hormone 
exposure, age at menarche and menopause, gender, and estrogens administered 
exogenously. These carcinomas are associated with postmenopausal women and 
they over express the estrogen receptor. 53 
Breast carcinoma can occur at any age, but is rare in patients younger than 25 
years. The peak incidence is 45-60 years. It is conventional to subdivide carcinoma 
of the breast into two main pathologic categories – in situ carcinoma and invasive 
carcinoma. 
WHO CLASSIFICATION OF BREAST TUMOURS64 is included in     
Annexure II. 
HISTOLOGIC TYPES OF BREAST CARCINOMA: 
The important determinants in the morphologic analysis of breast carcinoma are  
1. Whether the tumour is confined within the epithelium (in situ carcinoma) or has 
stromal invasion (invasive carcinoma). 
2. Whether it belongs to the ductal type or lobular type26,80,81. 
INVASIVE CARCINOMA: 
Tumours in which stromal invasion is appreciable are termed invasive 
whether an in situ component is present or not. Two major categories of invasive 
cancers are ductal type and lobular type44.  
The classification and distribution of various histological types of invasive 
carcinomas is as follows: 
Classification of histological types with distribution53: 
Invasive carcinoma Percentage(%) 
Invasive carcinoma NOS type  79 
Lobular carcinoma 10 
Tubular/Cribriform  carcinoma 6 
Mucinous carcinoma 2 
Medullary carcinoma 2 
Papillary carcinoma 1 
Metaplastic carcinoma <1 
 
 
INVASIVE DUCTAL CARCINOMA - NOS TYPE (IDC-NOS): 
Rosen (1975) et al says that this type constitutes 65-80% of breast 
carcinomas. According to WHO, the classification of Invasive ductal carcinoma -
NOS type tumour is one of exclusion: “Invasive ductal carcinoma is the most 
common malignant tumour, not falling into other categories of invasive breast 
carcinoma”64. Grossly, they have an irregular, stellate outline or nodular 
configuration with greyish white cut surface and yellow streaks (Fig 1). It can be 
associated with Paget’s disease of the nipple presenting as eczematous changes of 
the nipple (Fig 5).   
Microscopically, WHO classification requires a non-specialized pattern in 
more than 50% of the tumour area to be termed as NOS- type. Typically, 
infiltrative margins and trabecular, diffuse sheet like, acinar, nested, comedo 
patterns (Fig 2) are seen in combinations44,45.  
Paget’s disease of the nipple shows proliferation of atypical cells in the 
epidermis with large nuclei and clear cytoplasm (Toker cells) (Fig 6). Hormone 
receptor studies of IDC-NOS type shows that 70-80% of this tumour type had 
Estrogen, Progesterone receptor positivity44,64. 
 
 
INVASIVE LOBULAR CARCINOMA: (ILC) 
Foote and Stewart (1946) et al identified the term Infiltrating Lobular 
Carcinoma. Tavassoli (1992) documented that ILC of breast showed small cells 
with linear pattern of growth. This type constitutes 4.9-15% of all invasive breast 
cancers64. It is evidenced that it is commonly multicentric in comparison with other 
tumour types44. It is difficult to define it grossly because they are poorly delimited 
tumours. Microscopically, the cells are non-cohesive with eccentrically placed 
round or oval nuclei with small nucleoli and scanty cytoplasm. Indian file and 
targetoid patterns are noted (Fig 10)64. 
Dixan J M (1985) et al conducted receptor assay and revealed Estrogen, 
Progesterone receptor positivity in 67-92% of cancers45 and E-Cadherin 
negativity64. 
TUBULAR CARCINOMA64: 
This special type of tumour with a favourable prognosis shows well 
differentiated tubular elements with open lumen lined by a single layer of epithelial 
cells. These carcinomas measure between 0.2 cm- 2 cm in diameter.  The 
significant feature is the presence of open angulated tubules having single layer of 
epithelial cells. Tubular carcinoma is always positive for hormone receptors (ER, 
PR positive) and EGFR negative. Pure tubular carcinoma executes excellent long 
term prognosis.  
INVASIVE CRIBRIFORM CARCINOMA (ICC): 
This is an invasive tumour with good prognosis that grows in a cribriform 
pattern. ICC constitutes 0.8-3.5%. Microscopically, this tumour has well defined 
spaces formed by arches of cells (a sieve-like pattern) (Fig11). According to WHO, 
it shows estrogen receptor positivity in 100% and progesterone receptor positivity 
in 69% of cases64. 
MUCINOUS CARCINOMA: 
In 1852, Robinson RR et al has emphasised about gelatinous carcinoma of 
breast. The incidence rate is 0.8-6%64.  WHO classification describes: “large 
amount of extracellular mucin sufficient to be visible both macroscopically and 
microscopically around the tumour cells” 64. (Fig 3,4). 
Diab SG (1999)9 in his study documented estrogen receptor positivity in 73-
95%, progesterone receptor positivity in 79-84%. This tumour is negative for 
EGFR64. 
 
 
MEDULLARY CARCINOMA: 
Geschicker CF (1945) et al documented that this high grade tumour as a 
different entity in breast carcinoma. Grossly, the tumour is well circumscribed and 
soft in consistency53. WHO describes medullary carcinoma as “well circumscribed 
carcinoma with poorly differentiated cells and scanty stroma showing 
lymphoplasmacytic infiltration”(Fig 12).  In spite of the high grade of tumour, it 
carries good prognosis.64 
Immunohistochemical studies revealed estrogen receptors are negative64 
with particular immunophenotype (i.e) p53 positive, HER-2/neu negative.64 
PAPILLARY CARCINOMA: 
Foote and Stewart (1946) et al described it as “A rare carcinoma whose 
invasive component particularly is in the form of papillary formations”. Most of 
the previous literature about these tumours might include invasive and in situ 
papillary lesions.  Invasive papillary carcinomas constitutes < 1-2% of invasive 
breast cancers, and have good prognosis. Fisher et al found out that invasive 
papillary carcinoma is macroscopically circumscribed in 2/3 of cases64. Delicate or 
blunt papillae lined by tumour cell is the microscopic feature (Fig 13). Estrogen, 
Progesterone receptor positivity is seen in 80% of these tumours.59 
 
INVASIVE MICROPAPILLARY CARCINOMA: (Fig 14,15) 
The term was defined by Siriaunkgul S and Tavassoli FA who first defined 
nine cases. WHO describes this as a tumour characterized by small groups of 
tumour cells seen within clear spaces in the stroma that looks like dilated vascular 
spaces. It constitutes less than 2% of all invasive breast cancers. Grossly it has 
lobulated outline because of expansive growth pattern. It is noted for its 
peritumoural angioinvasion seen in 60% of cases64.  
METAPLASTIC CARCINOMA:  (Fig16) 
In 1984, Kaufman M.W documented breast carcinoma with 
pseudosarcomatous metaplasia. These tumours constitute less than 1% of all 
invasive carcinomas64. The mean age at presentation is 55 years. 
 WHO 2003 publication describes this tumour as “a heterogeneous group of 
tumours with intimate admixture of adenocarcinomatous components with 
predominant mesenchymal differentiation”.  
Macroscopically, the tumours are firm and on cut surface it is solid with 
pearly white to glistening areas due to squamous or cartilaginous differentiation. In 
a study by Carter et al, immunohistochemical analysis revealed positivity for 
smooth muscle actin, cytokeratin 14, and p63 in 39% of cases. Oberman HA 
(1987) et al showed that the hormone receptors were negative34.  
PHYLLODES TUMOUR (PT): (Fig 20, 21) 
Phyllodes tumours are biphasic tumours, with double layered epithelial 
component surrounded by an overgrowth of hypercellular mesenchymal areas 
typically seen in leaf-like structures64.  
Malignant phyllodes tumour (MPT) is a very rare breast malignancy and 
accounts for approximately 25% of all phyllodes tumours. This tumour 
metastasizes to lung, pleura and bone. Malignant phyllodes tumours with 
infiltrative margins are further classified into low-grade, and high-grade according 
to mitotic activity (with less or more than10 mitotic figures/HPF) and cellular 
atypia. Heterologous differentiation such as liposarcoma, osteosarcoma, 
chondrosarcoma or rhabdomyosarcoma can be seen64. Involvement of margins can 
be associated with local recurrences (frequency 27%). 
PROGNOSTIC AND PREDICTIVE FACTORS48: 
A prognostic factor is defined as a factor that is able to give information 
about the clinical course of the patient. They are the strongest predictors of death 
from breast carcinoma and are included in the American Joint Committee Cancer 
(AJCC) staging system. Predictive factors determine the likelihood of response to a 
particular therapy. 
 
Invasive carcinoma or in situ tumour: 
 Invasive carcinomas metastasize locally or distantly at the time of diagnosis 
in contrast to in situ disease.  
Distant metastases: 
 If distant metastasis is present, cure is unlikely and palliation can be 
achieved, for females with hormonally responsive tumors53. 
Tumour size: 
The tumour size has a good association with the nodal status and survival 
rate. It is one of the best prognostic factors for predicting Disease free survival 
(DFS) and distant metastasis in stage I breast cancer63. Women with node negative 
carcinomas under 1 cm in diameter have a prognosis like that of females without 
breast cancer44.  They have the 10-year survival rate of over 90%, whereas survival 
drops to 77% for cancer >2 cm 53. 
Study by Gohari MR, et al., (2006) showed that patients with tumour size 
larger than 5 cm have higher chance of metastasis16.  
Lymph Node Stage: 
Axillary lymph node status is the most significant prognostic variable for 
invasive tumours without distant metastasis.  
The clinical assessment of nodal status is likely to give inaccurate results 
with both false positive [eg. palpable nodes without metastasis] and false negative 
findings [eg. small lymph nodes with metastatic deposits (Fig 9)]53. Therefore, 
histopathological examination is required for accurate assessment (Susan C Lester, 
et al., 2004)96. Carter et al documented tumours having 4 or more axillary lymph 
nodes with metastasis usually have poorer survival regardless of tumour size. 
Fisher ER, et al., (1993) emphasised that the number of nodes with 
metastatic deposits has prognostic significance; patients with 4 or more involved 
nodes have a worse clinical outcome than with <4 involved nodes44. As a 
prognostic parameter, the best grouping is as follows (Rosai and Ackerman’s 
Surgical Pathology, 2004)44. 
1 – Negative nodes. 
2 – One to three positive nodes. 
3 – Four or more positive nodes. 
Histological type: 
Most poorly differentiated carcinomas have worse prognosis than their  
differentiated counterparts. Among special types, pure mucinous, tubular, and 
papillary carcinomas have good prognosis with more than 95% 5-year survival. 
The typical medullary carcinoma had a particularly favourable outcome with a 
92% 10-year survival. Histological type of carcinoma comparatively to grade has 
less importance for prognostication. So Pinder et al says that tumours should be 
typed and assigned grade to predict the choice of optimum treatment for breast 
carcinoma37. 
Excision Margins: 
It is the most important contributions in the management of breast cancer. 
Microscopic examination of the margin status is usually performed to find out the 
adequacy of surgical excision and the frequency of recurrence. The excision 
margins are usually marked with India ink. Schnitt SJ et al., (1994) in their study 
defined that  margin is positive when the  tumour is present at the inked margin, a 
close margin when tumour is present and negative margin when no tumour is 
present within one mm of the inked margin. It is emphasised that 5 year recurrence 
rate for those with negative, close, focally positive and more than focally positive 
margins were 0%, 4%, 6% and 21% respectively49. 
Vascular Invasion: 
Penetration of small lymphatic and blood vessels has relationship with 
metastasis and a poorer prognosis. It is difficult to delineate true vessels from 
artifactual spaces (Ellis IO, et al., 1996)55. Vascular invasion should be searched 
for, in the peritumoral area and it must have an endothelial lining 55,63. 
Reticulin stain, endothelial markers (CD 31 and CD 34) can be used for 
confirmation. Most of the previous reports are documenting that there is significant 
association between the vascular invasion and local recurrence, disease-free 
survival or overall survival (Pinder S, et al 1995)38. 
 Histological grade: 
Greenhough RB (1925)18 et al was the first to assess the  histological grade 
in breast cancer by assessing eight different morphological factors - the amount of 
gland formation, the presence of secretory vacuoles, cell size, nuclear size, 
variation in the size of both cells and nuclei, the degree of nuclear 
hyperchromatism and the number of mitosis. Patey and Scarff RW., et al (1928) 
highlighted on the amount of tubule formation, nuclear atypia and 
hyperchromatism. The mitotic figures were identified to be of less significance by 
them. 
In 1957, Bloom HJG, a radiotherapist and Richardson, a surgical researcher 
have come up with a numerical scoring system; the three factors-tubule formation, 
nuclear morphology and mitosis, was scored each on a figure of 1 to 3, giving a 
score of 3 to 9 points5. This Patey and Scarff method, modified by Bloom and 
Richardson was preferred as the grading system by the WHO (Ellis IO, et al., 
1992)64. Black MM, et al., (1955) re-studied the method advocated by Bloom 
(1950) and end up that nuclear morphology was most significant. Since both 
architecture (Bloom – Richardson system) and cell morphology (Black) have been 
associated with prognosis, they have been used together (Lash RH, et al., 1986). 
Elston has been the leader of this grading system, which is now termed as the 
Nottingham modification of the Scarff Bloom - Richardson System (SBR)55. 
The grading criteria for this system are: 
i) Tubule formation: 
Only structures with a clearly defined lumen, indicative of ductal or 
glandular differentiation are included. Spaces formed as a consequence of other 
mechanism, such as shrinkage artefact or cellular necrosis is excluded55.  
ii) Nuclear pleomorphism: 
In order to introduce a degree of objectivity, the size and shape of normal 
epithelial cells present in breast tissues adjacent to the tumour should be used as a 
reference point. If normal epithelial structures are not present in the tumour 
section, then it is usually possible to find inflammatory cells such as lymphocytes 
for comparative purpose. Allowance should be made for the fact that lymphoid 
cells have a relatively smaller overall size than epithelial cells55.  
iii) Mitotic counts: 
 Most significant modification in SBR method has been made by Ellis in the 
assessment of mitotic counts. Hyperchromatic nuclei is more likely to indicate 
individual cell necrosis than proliferation, and such nuclei should be excluded from 
the counts. Only figures which legibly accomplish and satisfy the morphological 
criteria for the different stages of mitosis - prophase, metaphase, anaphase and 
telophase are included in the count (Elston CW, et al., 1998)55. 
A minimum of 10 microscopic fields is counted at the tumour periphery 
where there is more proliferative activity (Verhoeven D, et al., 1990)55. Allocation 
of points is shown in the table64: 
The comprehensive grade of the tumour is acquired by adding the scor
factor giving a sum of 3 – 9 points. 
Points allocated for overall grade of the tumour:
3 - 5   – Grade I (Fig17). 
6 - 7   – Grade II (Fig 18). 
8 - 9   – Grade III (Fig 19). 
 
 
 
 
 
es for each 
Significance of Grading: 
The degree of differentiation in carcinoma of the breast is revealed in the 
histological appearance of the tumour and this feature forms the basis for the 
grading system5. Bloom and Richardson in his study of 1409 cases of breast 
cancers with 15 years follow up found that grading identified the malignant 
potential of the tumour. The real value of histological grading is in assessing the 
frequency of metastases and death. 
Multiple independent studies have shown that Nottingham grading system is 
equivalent to the lymph node status and more than that of tumour size in assessing 
the prognosis. Rakha et al found that high-grade tumours, with their risk of early 
recurrence and death need prompt use of adjuvant chemotherapy and grade 1 
tumours can be given long-term follow-up with or without less toxic systemic 
therapy40. 
Histologic grading should be done in every case of invasive carcinoma of 
breast. But some special types such as tubular, invasive cribriform and mucinous 
carcinoma by typing itself are comparable with the grade I status55, Classical 
Infiltrating lobular carcinoma are designated as grade 240. Medullary carcinomas 
are considered as grade 3 but have been found to have good outcome and grading 
is less significant. In most of the special types, the grade does not represent a 
prognostic factor9. 
Assessment of prognostic factors by multiple regression technique of Cox 
documented that only tumour size, histological lymph node status and histological 
grade have association with overall survival. Based on the coefficient of 
significance produced in the Cox analysis, a simple prognostic index has been 
formulated as follows55: 
NPI = 0.2 x tumour size + lymph node (1-3) stage + histological grade (1-3). The 
higher the value for NPI, the worse the prognosis. Three groups have been divided 
by devising cut off points. 
<3.4       - Good prognostic group (GPG). 
3.41-5.4 - Moderate group (MPG).  
>5.4       - Poor group (PPG)55. 
Thus grading seems to be meaningful in “Not otherwise specified” ductal 
carcinomas which account for more than 80 % of the breast cancers. 
HORMONE RECEPTORS: 
Over a hundred years ago, the hormone receptor sensitivity of breast 
carcinoma has been reported. Albert Schinzinger was the first surgeon who 
proposed that surgical oophorectomy can be offered as a treatment for breast 
cancers in 1889.  It took another sixty years for Etwood jenson and colleagues to 
discern an estrogen binding protein which is now called as the “Estrogen 
Receptor”.  Exogenous estrogenic harmones could have an effect upon the 
proliferation of  tumour cells has been observed by Haddow et al19 in 1940.  
Hence, he has laid the importance of non surgical endocrine therapy.  
Hormonal agents that is used for therapy can be classified  in to three major 
categories. They are gonadotrophin releasing hormone agonist and aromatase 
inhibitors. Tamoxifen that belongs to third category is nowadays the most 
commonly used agent which acts locally by restraining the action of hormones on 
the target tissues. 
 Later on,  Horwitz et al found that the status of progesterone receptor, a 
protein induced by the estrogen can make beneficial addition to the prognostic 
value afforded by estrogen receptor alone. 
ER, PR AS PROGNOSTIC AND PREDICTIVE FACTOR: 
The status of estrogen and progesterone receptors in an invasive malignant 
tumour of breast can play the role of both prognostic and predictive factor41.  
As a prognostic factor, ER and/or PR positivity can be correlated with 
decreased death rate and an improved survival when compared with ER, PR 
negative tumours35. It has been documented that 5-year overall survival is 83% in 
ER+/PR+ patients but it is reduced to 69% in the receptor negative individuals. 
The NSABP B-06 trial (National Surgical Adjuvant Breast and Bowel 
Project data) that has been carried out with early-stage breast cancer revealed that 
ER-positive patients had an improved 5-year Disease free survival (DFS) and 
overall survival (OS) of 74% and 92% respectively but this has been drastically 
reduced to 66% and 82% respectively in hormone receptor negative status41. 
Analysis of steroid hormone receptor status is a very precise tool that can 
indicate in advance the probability of usefulness of tamoxifen. The recently 
organised randomized trials with the application of tamoxifen as adjunct therapy in 
37,000 females who were affected with breast cancer58 illustrated that the same 
drug administered for 5 years end up with the outcome of relative decrease in the 
recurrence rate of 47% and mortality rate of 26% in individuals having steroid 
receptor positive cancers. When patients were treated with tamoxifen for five 
years, it reduced the probability of developing tumour in the opposite breast by 
47%41. It was not beneficial to the women with the receptor-negative tumours58. 
Jamil et al advocated hormonal therapy and chemotherapy preferentially to 
females who have attained menopause and showed that patients with ER+/PR- and 
ER-/PR- status who were offered the drugs responded well compared to 
premenopausal females26. 
ER, PR - AS BASIS FOR RESPONSE TO HORMONAL THERAPY: 
The importance of the study of hormone receptor status lies in the selection 
of individualised treatment strategy for breast cancer subtypes26. Clinically, the 
positive status can state in advance about the likelihood of response to drugs like 
selective estrogen receptor modulators and whether or not the patient will respond 
to hormone therapy. 
Recent advances in the characterization of different breast cancer types have 
intensified our focus on the discovery of druggable targets for the development of 
more selective breast cancer treatments. 
          Breast cancer-related deaths have markedly decreased with the discovery of 
endocrine agents (e.g. tamoxifen and aromatase inhibitors) that selectively target 
ER expressing breast tumours. This serves as a motivation to continue to define 
potential druggable targets for hormone receptor and HER2 negative (triple-
negative) breast cancers that do not respond to endocrine therapies or to 
trastuzumab and for which cytotoxic chemotherapy is the only systemic treatment 
option. In-depth characterization of breast tumours is imperative for the 
development of targeted therapies. 
Hormone receptor status as determined by immunohistochemistry correlated 
with therapy regimens like chemotherapy and hormone therapy26.  
The Immunohistochemistry assay has substituted the older methods like 
ligand binding assay and is nowadays preferred as the mode of choice for 
analysing the hormone receptors. It estimates the proportion of cancer cells 
expressing the positivity. 
To a greater extent, there is a notification that variations in the procedures 
and techniques of the assay used could make alterations in the results and 
interpretations. The changes can also be due to the study group of patients with 
distinct and modified clinical stages and aggressive phenotypes of carcinomas43. 
The outcome will also be influenced by inadequate fixation. So the 
specimens should be obtained immediately after the surgical procedures. The 
commonly used fixatives are formal-saline and neutral buffered formalin. The 
fixation should be quick and the fixative should be evenly distributed throughout 
the specimen41. 
A hybrid block which encompasses distinct tissues containing areas 
abundant with receptors admixed with receptor deplete and negative tissues should 
be used. It is likely that the tumour tissues that should be evaluated possess normal 
appreciable breast parenchyma to serve the purpose of positive internal control. 
The process should be repeated when difficulties are encountered in the staining of 
normal parenchymal tissue. 
 The type and grade of the tumour should also be considered so that they 
both have been proved to have impact on the interpretation of inferences. This is 
supported by the fact that the tumours that are well differentiated are highly 
improbable to yield negative results41. 
Scoring system: 
Various respective scoring methods have been imparted in the literature. The 
positivity should be depicted by taking in to account the staining in the nuclei of 
the tumour cell. It is important to estimate the entire invasive element of the 
tumour.  
The importance of establishing a definite scoring system is to make certain 
that homogeneity should exist between various laboratories. On considering this 
issue retrospectively, it is essential to bring emphasis to Allred score assigned by 
Craig Allred few years ago. In 2010, Asim et al added an adjunct for the 
widespread use of this method nowadays and supplemented by the study report 
that the sensitivity as well as the specificity of the Allred score was very high in 
contrast to other methods1. The score is allocated by the estimation of  two scores, 
first is the proportion score from 0 to 1, given by analysing the percentage of 
nuclei in the cells, having taken the stain and secondly, the intensity score from 0 
to 1 given by exploring the strength and magnitude of staining as negative, weak, 
average and intense. 
Both the scores are added to give the total score.  
Various rational motives for identifying both the hormone receptor positivity 
and analysing the intensity of the reaction of breast carcinomas are as follows: 
1. Several reviewed facts and materials about the evaluation of both receptors are 
accounted to the management of carcinomas with metastasis in the view of, greater 
the percentage and intensity of positivity of tumour cells, then higher the 
possibility of better outcome and effects to endocrine therapy41. 
2. Virtually, there would not be any anticipation of response in individuals with 
breast carcinomas which do not exhibit the staining pattern.  
3. The consideration of progesterone receptor along with estrogen receptor is ideal 
and worth. The tumours that have very low ER positivity but high PR positivity 
could still respond to hormonal treatment is the contributory evidence provided by 
the progesterone receptor.  
4. Even though the degree of staining is low in the tumours scoring 2 or less than 2, 
the adjuvant endocrine therapy has been proved beneficial in those patients too. 
This highlights and foregrounds that it is necessary to develop sensitive and 
standardised procedures which have the ability to trace out these low receptor 
levels.41 
From then until now, after the invention of  ER and later progesterone receptor 
(PR), vigorous and innovative efforts has been made on the relevance and 
importance of hormone receptors in breast cancer evolution, progression, 
metastasis, prevention and the management of Breast cancer.  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
The study group comprised of malignant breast lesions received in the 
Department of Pathology, Madurai Medical College, Madurai from the 
Government Rajaji hospital, Madurai during the period of July 2010 to June 2012. 
 During the study period, 151 trucut biopsies, 313 lumpectomies and 215 
mastectomy specimens were received. Out of these, 74 trucut biopsies, 37 
lumpectomies and 157 mastectomy cases were proved to be malignant.  41 trucut 
biopsies and 22 lumpectomy cases were followed by mastectomy. Out of the 157 
mastectomy specimens, 154 cases were malignant epithelial lesions and 3 cases 
were malignant phylloides tumour. This study group consisted of 157 cases of 
malignant breast lesions surgically treated by mastectomy.  
            Detailed clinical history of these 157 cases such as age, sex, menopausal 
status, laterality of the lesion, nipple discharge and clinical diagnosis were 
recorded in the proforma and tabulated in the master chart. (Annexure I and V)         
         Mastectomy specimens were bisected and fixed in 10% formalin for 24 – 48 
hours. Detailed gross examination pertaining to side and type of mastectomy, list 
of structures included in the specimen like skin, nipple, major and minor pectoralis 
muscles, fascia, axillary tissue, chest wall structures, weight, overall size of the 
specimen, dimensions of the skin, features of external appearance such as  
• shape and colour of skin 
• location and extent of skin changes (scars, recent surgical incisions, 
erythema, oedema, flattening, retraction and ulceration) 
• appearance of nipple and areola (erosions, ulceration, retraction, inversion) 
were noted. 
 They were cut at 1cm interval with special attention to include base, lateral 
margins, skin and ulcerated areas. On cut section, location of lesion, distance from 
the  nipple and skin,  tumour size, shape, consistency, colour, presence of necrosis, 
haemorrhage, calcification, attachment to skin, muscle, fascia or nipple and 
distance from cut margins, lymph nodes if present, number of nodes in each group 
(low, mid, apical axilla) and size of the largest node in each group were noted.   
The representative sections were taken from the tumour, nipple, pectoralis 
major muscle (in radical mastectomies), lateral and posterior surgical margins and 
palpable lymph nodes.  
         The tissue slices were processed in various grades of alcohol and xylol and 
subsequently embedded in paraffin wax. Paraffin sections of 4 µm thickness were 
subjected to haematoxylin and eosin staining.  
They were analysed for the tumour size, tumour grade, vascular and perineural 
invasion and pTNM classification was done. 
Histological assessment of tumour grade is done by Modified Richardson – Bloom 
Scoring system for 144 malignant epithelial lesions. Nodal status and margins 
involvement were recorded for all the cases. 
IMMUNOHISTOCHEMICAL ANALYSIS OF HORMONE RECEPTORS: 
Immunohistochemical analysis of hormone receptor assay was done for 
selective cases. It was done in paraffin embedded tissue blocks, by using the 
Supersensitive Polymer HRP system based on non-biotin polymeric technology 
that makes use of two major components, Super enhancer and poly- HRP reagent.  
The retrieved antigen was bound to primary antibody and then detected by 
the addition of secondary antibody conjugated with horse radish peroxidase 
polymer and DAB substrate. The score was calculated after adequate colour 
development which can be more readily visualized under a light microscope. 
           The step by step procedure is included in Annexure III. 
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Table 1 and Chart 1 shows the distribution of malignant breast tumours according 
to age. 4 cases were seen in 20 - 29 year age group (2.5%), 26 cases were seen in 
30 - 39 year age group (16.5%). Malignant tumours had a peak incidence in the age 
group of 40-49 years (35.7%), followed by 50- 59 years (20.4%). 26 cases were 
seen in 60 – 69 year age group (16.6%) and 13 cases were seen in the 70 - 79 year 
age group (8.3%). The mean age of malignant breast tumours observed in our 
study is 49.5 years. 
TABLE 1: 
Age group Malignant breast tumours 
No % 
20-29 years 4 2.5 
30-39 years 26 16.5 
40-49 years 56 35.7 
50-59 years 32 20.4 
60-69 years 26 16.6 
70 & above 13 8.3 
Total 157 100 
Range 24-79 years 
Mean 49.5 years 
S.D 11.9 years 
 
Sex incidence: 
All of the cases in our study who were surgically treated with mastectomy were 
females whereas the breast malignancies can occur in male breast also. 
CLINICAL FINDINGS: 
 Incidence according to Menopausal status: 
 In the present study, we have made a categorisation with regard to the 
attainment of menopause. 49 years has been taken as the outermost cut off point 
for premenopausal group. This has been preferred to make apparent that most of 
the women who had cyclical menstrual cycles were < 49 years, while at the same 
time older females >49 years had no menstruation or had occasional cycles. 
TABLE 2: 
Menopausal status No of cases Percentage (%) 
Premenopausal 86 54.78% 
Postmenopausal 71 45.22% 
 157 100 
Table 2 indicates 86 patients in our study were in the premenopausal age group 
(54.58%) and 71 cases were in the postmenopausal age group (45.22%). 
 
Laterality of malignant breast tumours: 
TABLE 3: 
Side No of Cases 
No % 
Left side 88 56.1 
Right side  68 43.3 
Bilateral 1 0.6 
Total 157 100 
From the table 3 and chart 2, it is evident that maximum number of cases had left 
sided breast tumours (56.1%) and 68 cases had right sided breast tumours (43.3%). 
Bilateral lesions comprised only 0.6% (1 case). 
CHART 2: 
Percentage of quadrant involved
S.no Quadrant 
1. Upper outer 
2. Lower outer 
3. Upper inner 
4. Lower inner 
5. Subareolar / central
 Total  
 
: 
TABLE 4: 
No of cases Percentage
75 47.77% 
24 15.29% 
21 13.37% 
10 6.37% 
 27 17.20% 
157 100 
 
 (%) 
Table 4 reveals that in the present study, 47.77% of cases presented with 
lump in the upper outer quadrant, followed by subareolar region (17.20%) and 
lower outer quadrant (15.29%). Other quadrants involved were upper inner 
(13.37%) and lower inner (6.37%). 15 cases showed involvement in two quadrants 
and 10 cases in all the quadrants. 25.47% (40/157) of cases presented with nipple 
discharge. 
Size of the tumour: 
TABLE 5: 
S.no Tumour size No of cases Percentage (%) 
1. ≤ 2 cm T1 26 16.56 
2. 2-5 cm T2 56 35.67 
3. ≥ 5 cm  T3 68 43.31 
4. Skin or chest wall T4 7 4.46 
 Total cases 157 cases 100% 
 
Table 5 shows 26 cases had tumours ≤ 2 cm (16.56%), 56 cases had tumours with 
size 2-5 cm (35.67%) and most of the tumours (68 cases) had ≥ 5 cm tumour size 
(43.31%). 7 cases had tumours with involvement of skin (4.46%). 
Axillary Lymph Node Status for Invasive Epithelial Tumours: 
TABLE 6: 
Lymph Node Stage   No of Cases Percentage  
Stage I (negative) 26 16.8% 
Stage II (1-3 positive) 74 48.1% 
Stage III (≥ 4 positive)  54 35.1% 
Total cases 154 cases 100% 
 
Table 6 and Chart 3 shows the percentage of cases in each lymph node stage. 
16.88% cases were of lymph node stage I, 48.1% cases have 1-3 positive lymph 
nodes and 35.1% of cases have 4 or more than 4 positive lymph nodes (stage III 
lymph node status). 
CHART 3: 
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In the present study, none of the patients presented with 
organs. 
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TNM staging of malignant epithelial tumours of the breast: 
Table 7 and chart 4 shows the percentage
cases were seen in stage I (
Maximum number of  72 cases (46.75%) were seen in stage III.
 
CHART 4: 
 of cases in each stage in our study. 
16.88%), 56 cases were seen in stage II (36.37%) 
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TABLE 7: 
S.no Stage No Of Cases Percentage (%) 
1. Stage I 26 16.88% 
2. Stage II 56 36.37% 
3. Stage III 72 46.75% 
 Total cases 154  100% 
 
 
 
 
 
 
 
 
 
DISTRIBUTION OF HISTOLOGICAL VARIANTS OF BREAST 
CARCINOMAS AND MALIGNANT PHYLLOIDES TUMOUR: 
TABLE 8: 
S.no Histological variants  No of cases Percentage (%) 
1. Invasive ductal carcinoma NOS type 138 87.89% 
2. Paget’ disease with IDC-NOS type 6 3.82% 
3. Invasive lobular carcinoma 1 0.64% 
4. Mucinous carcinoma 4 2.54% 
5. Invasive cribriform carcinoma 1 0.64% 
6. Papillary carcinoma 1 0.64% 
7. Micro Papillary carcinoma 1 0.64% 
8. Medullary carcinoma 1 0.64% 
9 Metaplastic carcinoma 1 0.64% 
10. Malignant phylloides tumour 3 1.91% 
 Total cases 157 100% 
 
 Table 8 and Chart 5 shows the distribution of histological variants in breast 
carcinoma and the malignant mesenchymal
cases (87.89%) were Invasive Ductal Carcinoma NOS type. 6 cases were 
associated with Paget’s disease (3.82%), 4
carcinoma and one each (0.64
carcinoma, Cribriform carcinoma, Papillary carcinoma, 
Metaplastic and Medullary carcinoma.  3 cases were 
(1.91%). 
 lesions. Among the 157 cases,
 cases (2.54%) were Mucinous 
%) in other special sub-types including Lobular 
Micropapillary, 
Malignant phylloides tumour 
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HISTOLOGICAL GRADE IN INVASIVE DUCTAL CARCINOMA NOS 
TYPE: 
Histological grading is done in breast carcinomas according to Modified 
Bloom-Richardson grading system (SBR).   
Only 144 cases which were invasive ductal carcinoma NOS type were 
included for grading because invasive tumour that belongs to special histological 
types have a predefined grade as follows. 
e.g. Tubular carcinomas are grade 1,  
Classic Lobular carcinomas are always grade 2 and  
Medullary carcinomas are grade 3 respectively. 
     Table 9 and Chart 6 shows that out of 144 cases of Invasive ductal carcinomas, 
not otherwise specified type (IDC - NOS type), 26 cases (18.05%) were seen in 
grade I, 72 cases (50%) were in grade II and 46 cases (31.95%) were in grade III. 
So in the present study maximum number of  cases were seen in grade II (50%). 
 
 
 
 
 S.no Histological grade
1. Grade I 
2. Grade II 
3. Grade III 
 Total cases 
 
TABLE 9: 
 No of cases Percentage 
26 18.05% 
72 50% 
46 31.95% 
144 cases 100% 
CHART 6: 
(%) 
 
 RELATIONSHIP BETWEEN AGE AND OTHER CHARACTERISTICS OF 
MALIGNANT TUMOURS: 
TABLE 10: Age and size of tumour: 
Age 
group 
                     Size in cms  
T1<2cm T2 2-5cm T3>5cm T4skin or 
chest 
Mean SD 
20-29  - 1 3 - 7.75 2.87 
30-39  7 12 7 - 4.62 3.18 
40-49  5 17 28 4 5.66 2.49 
50-59  9 13 10 - 4.42 1.9 
60-69  2 11 11 2 5.37 2.27 
70 & 
above 
3 2 6 1 4.85 2.12 
Total 26 56 65 7  
                                           ‘P’ value  - 0.0378 (Significant) 
 
 
 Table 10 and Chart 7 indicates that maximum number of cases, 17 and 28 
cases respectively in T3 and T4 tumour
Maximum mean size (7.75cm) is seen in the younger age group 20
mean tumour size in 30 - 39 year age group is 
5.66 cm, 50 – 59 year age group is 
79 year age group is 4.85 cm. The relationship between age and the mean size of 
the tumour is statistically significant with P value (0.0378).
 size is seen in the 40-49 years age group. 
4.62 cm, 40 – 49 year age group is 
4.42cm, 60 -69 year age group is 
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 CORRELATION OF AGE WITH OTHER PROGNOSTIC PARAMETERS: 
TABLE 11: 
AGE 
GROUP 
         GRADE  TNM STAGE NODAL STATUS 
I II III I II III Neg 1-3 >4 
20-29 - 2 2 - 1 3 - 1 3 
30-39 7 12 7 7 12 7 7 12 7 
40-49 5 28 17 5 17 32 5 29 20 
50-59 9 12 9 9 13 10 9 11 12 
60-69 2 15 7 2 11 13 2 16 8 
70-79 3 3 4 3 2 7 3 5 4 
TOTAL  26 72 46 26 56 72 26 74 54 
Table 11 indicates Maximum number of cases in grade I (9 cases) were in 
the age group of 50- 59 years. Out of the 4 cases in 20-29 year age group, 3 cases 
were in stage III. Maximum number of cases in grade III (17 cases), stage III (32 
cases) and nodal status with 1-3 positive lymph nodes (29 cases) and >4 positive 
lymph nodes (20 cases) fall in the age group 40- 49 years. 
CORRELATION BETWEEN HISTOLOGICAL GRADE OF TUMOUR 
AND OTHER FACTORS: 
TABLE 12:  Histological grade of Tumours and size of tumour: 
 
Grade of tumour 
Size of tumour ( in cms) 
Mean SD 
Grade I 1.98 0.1 
Grade II 5.0 1.91 
Grade III 6.93 2.22 
‘p’ 0.0001 (Significant) 
 
Table 12 and chart 8 shows maximum mean tumour size (6.93cm) was observed in 
high grade (grade III) tumours with significant statistical correlation with P value 
of 0.0001. 
 
 
 
 
CORRELATION OF HISTOLOGICAL GRADING WITH TNM STAGE:
S.no Stage 
1. Stage I 
2. Stage II 
3. Stage III 
CHART 8: 
 
TABLE 13: 
            Histological  Grading 
Grade I Grade II Grade 
No % No % No 
26 100% - - - 
-  46 92% 4 
-  26 38.24% 42 
 
III 
% 
- 
8% 
61.76% 
 Table 13 shows the correlation between TNM staging and modified Bloom and 
Richardson (Nottingham) grading. All of the cases of stage I disease were of grade 
I (100%). Among stage II cases, 92% were of grade II and 8 % were of grade III. 
Among the stage III cases, 42 cases (61.76%) were of grade III and 26 cases 
(38.24%) were of grade II. 
CORRELATION OF HISTOLOGICAL GRADE AND AXILLARY LYMPH 
NODE STATUS: 
Table 14: 
S.no Lymph node stage             Histological Grading 
Grade I Grade II Grade III 
No % No % No % 
1 Stage I 26 100% - - - - 
2 Stage II -  55 83.33% 12 16.67% 
3 Stage III -  17 32.69% 35 67.31% 
 
Table 14 shows the correlation between axillary nodal status and histological 
grade. All of the grade I cases were of lymph node stage I (100%).  83.33% of 
cases with 1-3 positive nodes were of grade II. Among grade III cases, 35 cases 
had 4 or more positive lymph nodes (67.31%) and 17 cases (32.69%) had 1-3 
positive lymph nodes (LN stage II). 
CORRELATIVE STUDY OF HORMONE RECEPTOR STATUS IN 
BREAST CARCINOMAS: 
        In the present work, the study of hormone receptor (ER, PR) status has been 
undertaken in 20 cases of IDC – NOS type. This included cases in each age group. 
The results are shown below.  
 
 
 
 
 
 
 
TABLE 15: ER status in relation to age groups (n=20): 
Age group Total no of cases No of ER+ cases No of ER- cases 
20-29 2 0 2 
30-39 2 1 1 
40-49 6 4 2 
50-59 6 5 1 
60-69 3 2 1 
70-79 1 1 0 
Total 20(100%) 13(65%) 7(35%) 
TABLE 16: PR status in relation to age groups (n=20): 
Age group Total no of cases No of PR+ cases No of PR- cases 
20-29 2 0 2 
30-39 2 0 2 
40-49 6 2 4 
50-59 6 2 4 
60-69 3 1 2 
70-79 1 0 1 
Total 20 5(25%) 15(75%) 
 
Table 15 and 16 shows the ER/PR status in correlation with different age 
groups. It was observed that in the total 13 ER positive cases and total 5 PR 
positive cases, majority of the cases were observed in the age group of 50-59 years 
and 40-49 years, but the ER positivity was higher in the age group 50-59 years 
compared with the age group of 40-49 years.  
In the age group of 50-59 years, 83.33% (5 of 6 cases) were positive for ER 
and 2 of 6 cases (33.33%) were positive for PR. The percentage was found to be 
66.66% (4 of 6) for ER positive cases and 33.33 % (2 of 6) for PR positive cases in 
the age group of 40-49 years. There were 2 cases in age group 20 – 29 years, 1 
case in 30-39 years age group, 1 case in 60 – 69 age group respectively were 
negative for ER. 
HORMONE RECEPTOR STUDIES IN CORRELATION WITH 
MENOPAUSE: 
ER, PR hormone receptor study by immunohistochemistry was done for 10 
patients of the premenopausal age group and 10 patients of the postmenopausal age 
group with IDC NOS type and the results are shown below: 
 
 
TABLE 17: 
Hormone receptor study in correlation with menopause: 
ER/PR STATUS Premenopausal (n=10) Postmenopausal(n=10) 
ER+, PR+ 2(20%) 3(30%) 
ER+, PR- 3(30%) 5(50%) 
ER-, PR- 5(50%) 2(20%) 
 
From the table 17 showing the correlation of menopausal status with ER and 
PR status, it is evident that the hormonal positivity was greater in postmenopausal 
(30%) cases than that in premenopausal cases (20%). ER positivity was 80% (8 of 
10 total postmenopausal cases) in postmenopausal period and 50% (5 of total 10 
premenopausal cases) in premenopausal period. PR positivity was 30 % (3 of 10 
total postmenopausal cases) in postmenopausal period which was higher than 20% 
(2 of total 10 premenopausal cases) in premenopausal patients.   
In a total 13 ER positive cases, 61.54% (8 of 13 total positive cases) was 
observed in postmenopausal period and 38.46% (5 of 13 total positive cases) was 
observed in premenopausal period. In a total of 5 PR positive cases, 60% (3 of 5 
total positive cases) was observed in postmenopausal period and 40% (2 of 5 total 
positive cases) was observed in premenopausal period. The overall percentage of 
the receptor status of the patients showed that estrogen receptor positive and 
progesterone receptor negative tumours (ER+ and PR-) were highest in 
postmenopausal patients in the study group (50%). In the premenopausal group of 
patients, ER- PR - tumours were the highest which constitutes 50% whereas ER+ 
PR + tumours constitute only 20%. 
ER, PR study in different histological types of breast cancers: 
In correlating the ER, PR status with different histological types of breast 
cancers, one case of Papillary carcinoma was positive for both ER and PR. One 
case of Infiltrating lobular carcinoma was positive for ER and focally positive for 
PR. One case of Mucinous carcinoma was positive for ER but negative for PR. 
One case each of Metaplastic carcinoma and Medullary carcinoma in the present 
study is negative for ER and PR. 
 
 
 
 
 
DISCUSSION 
Breast is one of the commonest sites of primary neoplasms as it is influenced 
by the action of hormones. It stands as the second common cancer among south 
Indian females6,31.  In an overview, one lakh patients are annually diagnosed with 
breast cancer in India. In accordance with the ICMR-PBCR data, breast cancer 
comprises > 30% of all cancers and more prevalent in urban women31. In the rural 
areas, after the cervical cancer, breast cancer is the second most common cancer in 
females. 
There appears to be a wide variation in incidence between countries, and 
also within any country and this variation in incidence may be because of more 
widespread screening programmes and alterations in the registration procedures in 
certain countries, but there appears to be a real and genuine increase in the 
incidence not accounted for by these factors 2. This highlights the importance of 
early diagnosis and appropriate management in our country. 
Pathology has performed the “gold standard” role in diagnosing breast 
carcinoma over a long period of time. Histopathology is still considered to be the 
most sensitive method in diagnosing breast malignancies in comparison with the 
other currently available imaging techniques. The morphologic prognostic factors 
(tumour size, lymph node status and histological grade) have been used as reliable 
parameters in assessing the clinical outcome, survival and individualised treatment 
strategies. These parameters that are assessed by the pathologist represent the basis 
for categorising the patients in to low risk and high risk groups55.  
COMPARISON OF INCIDENCE OF MALIGNANT BREAST LESIONS:  
TABLE 18: 
S.no Name and year of study Incidence rate 
1. Indian Cancer Society, Mumbai (2001-2003)  27.47% 
2. National Cancer Registry Programme (ICMR) report 
(2001-03)  
25%  
3 National Cancer Registry programme, Chennai31, 
2008 
28.3% 
4 All India Institute of Medical Sciences, New Delhi 
2009 -2010 
24.3% 
5 National institute of pathology, New Delhi32, 2011 26.3%     
6. Present study 23.12% 
As per the reports mentioned in the table 18, current incidence in Chennai is 
at 28.3%31. In our study the prevalence is 23.12%, which is in close correlation 
with other studies mentioned in the table. 
COMPARISON OF AGE INCIDENCE IN PATIENTS WITH BREAST 
CANCERS: 
TABLE 19: 
S.no Age group Pals et al Reeni malik 
et al 2003 
Vissa et al 
201161 
Present 
study 
1 20-29 10.4 5.36 4.16 2.5% 
2 30- 39 26.1 15.66 29.16 16.5% 
3 40-49 33 69.95 20.83 35.67% 
4 50-59 19.0 69.95 45.83 20.4% 
5 60-69 8.0 - - 16.6% 
6 70-79 2.4 - - 8.3% 
While the incidence of breast cancer in western countries is most common in the 
postmenopausal age group, ie in their 60s and 70s, the incidence is somewhat 
different in India with pre-menopausal patients constituting about 50% of all 
patients. 
              The age incidence is between 41- 50 years in a study conducted by WHO. 
In concurrence with the aforementioned studies in table 19, our current study also 
reveals that the age of peak incidence of malignancy is 40 - 49 years constituting 
35.67% of cases. This correlates very well with the study of Pals et al. The mean 
age in our study is found to be 49.5 years and the age range is found to be 24 – 79 
years which is correlating well with the study conducted by khairy et al (age range 
24 -81 years)17 and Emmanuel A et al 2011 (mean age -48.12 years)11. 
CLINICAL PRESENTATION OF BREAST MALIGNANCIES: 
Laterality: 
TABLE 20: 
Side Samir S et al48 Emmanuel A et 
al 201111 
Present study 
Left 54.8 50.6 56.1% 
Right 45.2 48.9 43.3% 
Bilateral - 0.6 0.6% 
In the present study, most of the patients presented with left breast lump (56.1%) 
as the chief presenting symptom. Table 20 indicates that this finding correlates 
with the results of Emmanuel A et al 201111. Most of the neoplasms are found in 
the upper outer quadrant (65 cases). This is in correlation with the findings of kene 
TS et al and Vincent et al27 who found that the left breast was frequently involved 
in their study (62.1%), and the upper outer quadrant was the most commonly 
affected site (60.7%). Bilateral breast carcinoma constituting a very small 
proportion of all breast carcinoma cases (l.l-2.4%) is reported in our study in a 
patient aged 36 years with incidence rate of 0.6% which is a rare occurrence as 
emphasised by Eleni Tousimis et al10. The histopathological type of both the 
tumours is IDC – NOS type. The right sided tumour measures 4 cm in greatest 
dimension with TNM stage II and histological grade II and the left sided tumour 
measuring 1.5 cm is in stage 1 and grade I.  Eleni Tousimis et al10 in his study 
about the bilateral synchronous breast cancers suggested that they are 
independently occuring tumours rather than metastasis15. Khairy et al17 in his study 
found the same histological type in 71.5% of cases of bilateral breast cancer. 
Jobsen et al25 in his study demonstrated that the patients showing bilaterality 
had a higher distant metastasis (30.8% versus 15.1%, p=0.028) and there is high 
recurrence rate (29% versus 16%) than those with unilateral lesions. Hence it is 
emphasised that the bilateral breast carcinomas should be treated aggressively and 
advocated regular screening for distant metastasis. Also the patients with unilateral 
disease should be advised to undergo regular screening of the contralateral breast. 
 
MENOPAUSAL STATUS: 
In our study, majority of the patients belonged to premenopausal age group 
(86 cases, 54.78%). But this finding is more than the observation of Suvarchala SB 
et al who observed more number of postmenopausal patients (73.4%) in their study 
group54. 
Nipple discharge: 
          When the patient presents with nipple discharge, it is considered to be 
pathologic when it is spontaneous, persistent and contains gross or occult blood. 
As per the study by Richard J Santen et al46, among female patients referred to 
physicians with the presenting symptoms of breast disorder, 6.8% have nipple 
discharge46. But in our study, 25.47% of cases (40 out of 157 cases) presented with 
nipple discharge. 
Vissa et al emphasised that there exists some similarities between the risk 
factors for the development of Fibrocystic disease (FCD) and those of breast 
carcinoma61. Fibrocystic disease exhibit long term risk for the development of 
breast carcinomas and that risk is doubled in patients with complex features 
including atypical nuclear characteristics, ductal hyperplasias or a family history of 
breast carcinoma61. In our study 3 cases of invasive breast carcinomas are 
associated with Fibrocystic disease confirming the relative risk of benign 
proliferative breast diseases for the later development of invasive carcinomas. 
SIGNIFICANCE OF PROGNOSTIC AND PREDICTIVE FACTORS IN IDC 
–NOS TYPE: 
It is evident that difficulties prevail in the prediction of the clinical outcome 
of primary breast carcinoma. Some patients are cured by local therapy, and survive 
for many years. Some other patients experienced early recurrence of the disease 
and died shortly after. It would be useful to identify individual patients who have a 
low or high risk of relapse in order to plan the appropriate management of that 
patient’s breast cancer. Patients with a low risk of recurrence can be spared the 
potential toxicity associated with aggressive therapy, while patients with tumours 
that are most likely to recur could be given aggressive adjuvant therapy. Therefore 
a team work is essential and that should be done by the clinicians and the 
pathologists in order to select each patient’s treatment, according to prognostic and 
predictive factors. 
Hence the diagnostic histopathologist is in an ideal position to convey the 
clinicians with significant useful prognostic information by the routine 
examination of mastectomy specimens. In our study with 157 malignant tumours 
of breast, we have made an attempt to assess the various prognostic parameters 
which are of clinical importance in order to decide about the individualised 
treatment strategy. 
 
COMPARITIVE STUDY OF TUMOUR SIZE:  
For prognostic correlation the tumour size should be assessed on 
pathological specimens only, because the clinical measurement is notoriously 
inaccurate. In our study, the size of the tumour ranges from 1.5 to 15 cm and the 
mean size is 5.17 cm (S.D. 2.51 cm). This corresponds with the study of Mudduwa 
et al28 who found in their study that the tumour size ranged from 0.2 to 14.2 cm, 
mean size is 3.52 cm wherein the mean size is comparatively more in our study 
(5.17cm). 
 
 
 
TABLE 21: 
Tumour size Gohari MR16, et al, 
(2006) 
Onitilo et al35, 
2009  
Present study 
No of cases 
(n=117) 
% No of cases 
(n=1134) 
% No of cases 
(n=157) 
% 
< 2  T1 21 18.6 810 71.4 26 16.56 
2-5  T2 57  50.4 262 23.1 56 35.67 
>5   T3 27 23.9 53 4.7 68 43.31 
Skin or chest wall T4 8 7.1 - - 7 4.46 
In our study, majority of the cases (72/154) have the tumour size >5 cm in 
maximum dimension constituting 43.31%. Table 21 indicates that this finding is 
comparatively more than the western literature by Onitilo et al35 where majority of 
cases falls within the tumour size < 2 cm in 810/1134 cases (71.4%).  
This indicates that majority of cases in our study presents in the late stage as 
size of the tumour is a time dependant variable in contrast with the western 
countries where the breast tumours are diagnosed in the early stage <2cm because 
of adequate screening programs and awareness. 
COMPARITIVE STUDY OF AXILLARY NODAL STATUS: 
 
  
TABLE 22: 
S.no Name of the study No of cases Lymph node status 
I (node 
negative) 
II(1-3 
positive) 
III(>4 
positive) 
1 ONITILO et al35 1134 61.2 35 - 
2 Uribe et al59 7,798 67 33  
3 Christopher et al8 5750 57.8 17.1 8.7 
4 Bharat et al 200552 569 19.8          80.2 
 Present study 154 16.89 48.05 35.1 
 
Table 22 indicates in the present study, patients with positive 1-3 nodes and 
more than 4 positive lymph nodes constitutes 48.05% and 35.1% respectively 
correlating with the Indian report of Bharat et al 200552.  The most important 
benefit of axillary lymph node dissection (ALND) is the prognostic information it 
gives in deciding about systemic therapy. Patients with four or more involved 
nodes at initial diagnosis have a significantly worse outcome than node-negative 
cases, regardless of the duration of the disease-free interval. Positive axillary nodal 
status is considered as a marker of an aggressive phenotype23. 
DISTANT METASTASIS  
In the present study none of the patients presented with distant metastasis. 
But in the study conducted by Agarwal et al,39 it is documented that 6-25% of 
individuals with breast cancer in India have metastasis to distant organs at the time 
of presentation. 
COMPARITIVE STUDY OF TNM STAGING: 
TABLE 23: 
S.no Name of the study No of cases                     Stage(%) 
I II III 
1 Onitilo  et al 200935 1134 56.4 36 7.7 
2 DJ Uribe et al59 7,798 53 38 9 
3 Christopher et al8 5750 51.6 37.7 6.3 
4 Agarwal et al15,lucknow  2007 544 4 34 51 
5 Vinod et al60, New Delhi2005 487 16 74 - 
6 Present study 154 16.8 36.37 46.75 
 
Table 23 shows that Pathological staging of breast carcinomas in our study 
showing 16.8% of the tumours presenting in stage I disease which is in correlation 
with the study of Vinod et al60. 36.37% are seen in stage II, 46.75% in advanced 
stage III, correlating with the study by Agarwal et al15 which are previous Indian 
reports. 
 But the studies done in developed countries have shown that more 
percentage of cases are seen in stage I disease which implies that the breast 
carcinomas are detected in an early stage in the developed countries. 
INCIDENCE OF HISTOLOGICAL TYPES: 
In our study Invasive ductal carcinoma NOS type observed in 144 cases 
stands as the most common carcinoma of the breast (91.71%). In that 6 cases are 
associated with Paget’s disease.  
Few rare neoplasms like Invasive lobular carcinoma, Cribriform carcinoma, 
Medullary carcinoma, Mucinous carcinoma, Invasive papillary carcinoma, 
Micropapillary carcinoma and Metaplastic carcinoma are also observed in our 
study. 
 
 
  
 
 
TABLE 24: 
S.no Histological types Ivar et 
al24 2010 
Emmanuel et 
al11 2011  
Mauro 
et al30 
Current 
study 
1 IDC – NOS type 81.4 87 80.63 87.89% 
2 IDC with Paget disease 1.5 - 1.05 3.82% 
3 Invasive Lobular carcinoma 6.3 3.6 1.05 0.64% 
4 Cribriform carcinoma - - 1.05 0.64% 
5 Mucinous carcinoma 1.5 1.8 2.62 2.54% 
6 Medullary carcinoma 1.1 1.2 0.52 0.64% 
7 Papillary carcinoma 1.2 0.6 2.09 0.64% 
8 Micropapillary  carcinoma 1.2 - 0.52 0.64% 
9 Metaplastic carcinoma 1.2 - 1.05 0.64% 
10 Malignant Phylloides 
tumour 
- 1.8 0.52 1.91% 
 
Table 24 shows that the Incidence of histological types in our study correlates well 
with the study of Emmanuel et al 201111 and Mauro et al30. Other rare special types 
which constitute <1% also correlate with other studies. 
COMPARITIVE STUDY OF CASES IN EACH GRADE WITH OTHER 
STUDIES:  
Histological grading is one of the validated prognostic variable and its exclusion 
from clinical decision making may result in overuse of adjuvant therapies in breast 
cancer. The most widely incorporated system of Elston - Ellis system which 
represents a modification of SBR system is used in our study. 
TABLE 25: 
S.no Name of the Study No of cases                 Grade 
I II III 
1 Frkovic-grazio and bracko 
et al., 200240 
270 38 38 24 
2 Warwick et al., 200462 1988 23 37 40 
3 Williams et al., 200665 1058 20 46 34 
4 Rakha et al., 200840 2219 18 36 46 
5 Thomas et al., 200957 1650 26 45 29 
6 Blamey et al., 200913 16,944 29 41 30 
7 Present study 145 17.9 49.7 32.4 
 
Table 25 shows that in our study, most of the breast cancers are in the grade II 
which correlated with the study of Williams et al., 200665. But in comparison with 
most of the western literature where more cases are picked up when they are as 
grade I lesions, our study shows 32.4% of cases in grade III. As per the previous 
reports, high grade lesions have early recurrence and metastasis and so there is 
justification for prompt use of chemotherapy and low grade lesions can be 
subjected to long term follow up with or without systemic therapy. Thus 
assessment of histological grade when carried out adequately is an important 
determinant of breast cancer prognostication and should be evaluated to define the 
individualised treatment. 
Thus, applying the algorithm of clinical determinants like TNM staging 
which takes in to account the tumour size, nodal status and distant metastasis  and 
histopathological types and grading in our study, it could be possible to identify 
individual group of patients whose prognosis is so good or so poor. It is also 
possible to comment whether the aggressive adjuvant therapy is warranted by the 
histopathological parameters and the results are correlating with the previous 
Indian studies and reports.  
CORRELATION OF AGE WITH OTHER PROGNOSTIC VARIABLES:  
As age is also a prognostic factor mentioned in the literature, we have made 
an attempt to correlate the age of the patient and the TNM classification at clinical 
presentation.  
Out of the 4 cases in 20-29 age group in our study, 2 cases had tumour size 
more than 5cm. Maximum percentage of 19.11% (>5cm) is seen in 40-49 year age 
group compared to older age group. 
These observations are correlating with the study of Schnitt et al and Pascal et al 
who ascertained through their observations that the tumours in young patients are 
more commonly seen with increased tumour size33,36. 
In our study, younger patients frequently have >4 positive lymph nodes with 
20 out of 54 (12.99%) in 40-49 year age group wherein it is 4 out of 54 (2.6%) in 
70-79 age group. This correlates with the observation by Paul et al14 who observed 
that 37% of patients who were less than 40 years in contrast with only 25% of 
patients > 40 years presented with lymph node metastasis. 
We found that the mean age was high in patients with stage I disease (49.5 
years) when compared with the mean age of women with stage III disease. In our 
study out of the four patients in 20-29 age group, 3 cases were found to be in stage 
III. This observation is similar to that of Foo CS, et al., (2005)12 who has come 
with the observation that the younger patients have tumors with advanced stage 
and poorer prognostic parameters. Hanna et al, 2009 emphasises that overall 
survival is poor in younger patients20 (74.7% in 20 – 34 years vs 87.8% in 50 – 69 
years) despite the aggressive adjuvant therapy to which they are subjected. The 
factors that are thought to be responsible for worse prognosis in young women are 
late presentation and more aggressive tumour biology. 
Age and histological grade: 
Our study results show out of the 4 patients in 20 - 29 year age group, 2 
cases each is seen with grade II and grade III tumours respectively. Most of the 
patients (17 out of 46) in grade III are in the 40-49 age group (11.81%). 
This inference is in parallel with the study of Schnitt et al and Pascal et al 
who observed that younger age group patients usually have breast carcinomas with 
grade 3 histological features33,36 and greater tumour size. 
CORRELATIVE STUDY OF HISTOLOGICAL GRADING WITH OTHER 
PROGNOSTIC VARIABLES: 
Cases of invasive ductal carcinoma were alone included in this correlation. We had 
144 cases in this category. 
Size and grade: 
In analysing the cases of breast carcinoma, we attempted a correlation 
between the histological grade of malignancy and the mean tumour diameter. We 
found in grade I lesion the mean tumour size was 1.98 cm, for grade II lesions it 
was 5 cm and grade III lesions had a mean tumour size of 6.93 cm. These results 
were statistically significant with a P value of 0.0001 (Table 12) This correlates 
well with the results of Sundquist M, et al.,29 who has shown that the accurate 
estimation of the tumour size together with the grade and lymph nodal status are 
documented statistically significant predictors of survival . 
Lymph Node Status and Grade: 
Axillary node involvement is an important prognostic parameters in the 
management of breast cancer.  
Rack and Gerber et al., found that primary lymph node involvement is not only a 
time-dependent indicator for tumour extension, but also indicates tumours with 
aggressive biological behaviour.  On correlation of lymph node stage with the 
histological grade of the tumour, it is found that among grade II, maximum number 
of cases (55 out of 72) with 83.33% have positive 1-3 lymph nodes. Most of the 
grade III cases (35 out of 46 cases with 76.09%) have > 4 positive lymph nodes. 
This is similar to the finding of Hung et al who documented that higher histologic 
grade was associated with more positive lymph node metastasis (P 0.001)51. 
TNM stage and Histological grade: 
There is an excellent correlation between the TNM staging and histological 
grading. As out of the 56 cases presenting as stage II disease, 46 cases fall into the 
grade II category and out of the 72 cases presenting as stage III diseases, 43 cases 
(62.32%) belong to grade III followed by 26 cases of grade II malignancy. This 
finding is similar to that of Rosen PP, et al., who found significant poorly 
differentiated features in malignancies with advancing stage. Hensen and freedman 
et al found that the 5-year relative survival rate for Stage I, Grade 1 tumours was 
99% and it is reduced for Stage I but Grade 221 tumours. In stages II-IV, histologic 
grade has important prognostic role. Thus assessing histological grade with staging 
improves the prediction of outcome. 
HORMONE RECEPTOR STATUS IN BREAST CARCINOMAS: 
As Breast cancer is hormone dependant and the tumour cell population that 
expresses ER positivity depend on estrogen to grow. Hence, anti-estrogen 
hormonal therapy blocks the receptors so that the cancer cells may undergo death. 
Onitilo et al.,35 2009 documented that ER+,PR+ tumours have a lower incidence of 
recurrence and a longer disease-free interval, regardless of tumour size or lymph 
node status54. Thus, hormone receptor positive tumours tend to have a significantly 
longer disease free survival than the receptor negative tumours7,26,43. Therefore, in 
our study we attempted to know the hormone receptor status in selected 20 cases of 
invasive epithelial malignant tumours. 
In a study conducted by Rhodes et al., 2000 in 7016 breast carcinomas, it 
was found that estrogen, progesterone receptors were positive in 54.8%, negative 
for both receptors in 22.1% of cases43. 
Col.V. Dutta et al (2008) conducted a study in 75 breast cancers in Armed 
Forces Medical College, Pune and on evaluation found that 33% of (25/75) cases 
expressed ER, PR or both whereas 67% (50/75) were found to be negative for both 
the receptors.  This study reveals that negativity for receptor status is higher in our 
Indian subset of tumours compared with western population. 
Tanuja Shet et al.,56 (2009) studied hormone receptor expression in the last 8 
years from 1999 to 2006 in a cancer referral centre in India. A total of 11,780 cases 
were reviewed. The percentage of hormone receptor expression varied from 52% 
to 57%. 
In the present study among the twenty cases in which hormonal receptor 
study has been done, only estrogen receptor positivity is seen in  65%  of cases and 
both receptors were negative in 35% cases (Table 15 & 16). Hence this study is 
comparable with the studies conducted in the Indian subset of tumours. There 
appears to be a minimal variation in receptor expression; this could be explained 
by differences in the technique of evaluation and inter-laboratory quality control 
variations. 
CORRELATION OF ER, PR STATUS WITH AGE AND MENOPAUSE: 
In the present study, on correlating the hormone receptor status with the age 
group, it was found that the positivity increases in older age group (50-59 years) 
which is correlating with the results of Suvarchala SB et al54 whose observation is 
that the receptor positivity status increases with age and also with many previous 
reports. 
Kaiser Jamil et al26 compiled with his observations that the individualised 
therapy can be offered to the patients by studying the ER, PR status on the basis of 
menopausal status. The overall percentage of the receptor status shows that 
Estrogen positive and progesterone negative tumours (ER+ and PR-) are more 
common in postmenopausal patients in the present study group (50%). The 
hormone negativity is more common in the premenopausal group of patients 
(50%). 
 This is in correlation with the most previous studies which emphasised the 
menopausal status suggesting that the degree of receptor positivity is lower in 
premenopausal women than the postmenopausal age group (Kenneth et al). The 
present study is also very well correlating with the study by Kaiser Jamil et al26 
who found greater number of ER+PR- cases in the postmenopausal age group 
(29.11%). 
Kaiser Jamil et al26 in his study also correlated the receptor status in breast 
cancer patients with therapy regimens like chemotherapy, hormone therapy with 
various medications. Postmenopausal women with ER+/PR- and ER-/PR- tumours 
who have been treated with the combination of these medications manifested better 
outcome in the form of tumour regression and decreased mortality than the 
premenopausal women.  
ER, PR status in different histological types: 
In different special types of breast cancers, it was found that 25% (5 of total 
20 cases) of IDC - NOS type were positive for both ER and PR. This is low when 
correlating with the previous literature which reported 70-85% positivity in IDC-
NOS type. This can be accounted by the fact that hormone receptor positivity 
varies according to the race, ethnicity, differentiation and aggressiveness of the 
tumour. In correlation with the literature by Suvarchala SB et al,54 the Lobular 
carcinoma is ER positive and has focal PR positivity whereas the Mucinous variant 
is ER+ but PR-. This can be accounted by the difference in standardisation 
procedures and fixation processes affecting the results. In correlation with the 
literature by Uribe et al59, the Medullary and Metaplastic carcinomas are negative 
for ER and PR and the Papillary carcinoma is positive for both. 
 
SUMMARY 
 In the two year study period from June 2010 – July 2012 in the Department 
of pathology, Madurai medical college, the breast lesions accounted for 679 cases. 
Out of this, this prospective study by assessing 157 cases of malignant tumours of 
breast treated by mastectomy with the clinical parameters, light microscopic 
findings and study of hormone receptors by Immunohistochemistry, the following 
conclusions are made and presented. 
1. The incidence of malignant breast tumours is 23.12%. 
2. Malignant neoplasms commonly occur between 40-49 years accounting for 
35.7%. All the 157 mastectomies included in the study are female patients only. 
Left sided breast lump is the commonest presentation (88/157 cases) and the 
Upper, outer quadrant is the usual site for the breast lumps (75/157 Cases). 
3. Out of the 157 cases, 86(54.78%) cases are in premenopausal age group and 71 
cases (45.22%) are in postmenopausal age group. Malignant tumours in our study 
are common in premenopausal age group. 
4. Out of 157 cases, 144 Invasive Ductal Carcinoma (NOS) are encountered in this 
study and it is the commonest malignant Neoplasm constituting 91.71%. Out of 
this, 6 cases (3.82%) are associated with Paget’s disease. 4 cases are Mucinous 
carcinoma constituting 2.54%.  Other special types such as Lobular, Cribriform, 
Papillary, Micropapillary, Medullary and Metaplastic Carcinoma (one case in each 
type) constitute 3.54%. 3 cases are Malignant phylliodes tumour constituting 
1.91%.  
5. Tumours with size <2 cm are seen in 26 cases (16.56%), 2-5 cm seen in 56 cases 
(35.67%), more than 5 cm seen in 68 cases (43.31%). 7 patients (4.46%) presents 
with tumours extending up to skin. Most of the breast malignancies in our study 
have > 5 cm tumour size. 
6. Node negative cases are 26 (16.89%), 74 cases (48.05%) presents with 1-3  
lymph nodes with metastatic deposits and 54 cases (35.1%) presents with >4 
positive lymph nodes. Majority of cases show 1-3 positive lymph nodes.  
7. 26 cases (16.88%) are in TNM stage I, 56 cases (36.37%) in TNM stage II and 
72 cases in TNM stage III (46.75%). Maximum number of cases are seen in TNM 
stage III. 
8. Grading is a very beneficial protocol in assessment of prognosis and 
management. 26/144 cases of IDC-NOS type are seen as grade I lesions (18.05%), 
72/144 cases as grade II lesions (50%) and 46/144 cases (31.95%) as grade III 
lesions. Most of the epithelial malignancies are seen as grade II lesions.  
9. The breast carcinomas in young women have mean tumour size 7.75 cm, most 
of them with TNM stage III disease at presentation and of higher histological 
grade. 
10. Histological grade as prognostic tool correlates well with other prognostic 
variables like tumour size, axillary nodal status and TNM stage. 
11. In the hormone receptor study done in 20 selective cases of IDC-NOS type (10 
cases in premenopausal age group and 10 cases in postmenopausal age group), 
estrogen receptor positivity is seen in 65% of cases, negativity for both ER and PR 
receptors in 35% of cases with increase in positivity in older age group (50-59 
years).  
12. ER+, PR- tumours (5/10 cases) are more prevalent in postmenopausal age 
group constituting 50%. 
13. Special histological variants like Papillary Carcinoma, Lobular Carcinoma are 
positive for ER and PR. Medullary and Metaplastic variants are negative for both 
receptors. Mucinous variant is positive for ER and negative for PR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
The present prospective study of clinicopathological correlation of breast 
carcinomas highlights the importance of evaluation of clinical parameters and their 
correlation with the prognostic significance of histopathological parameters.  In 
this analysis, it is found that the number of patients presented with advanced stage 
and grade is more in younger age group than older age group. 
So we conclude that an appropriate clinical evaluation of patients along with 
the assessment of  basic histopathological prognostic parameters and 
Immunohistochemical study of  hormone receptor in breast cancer patients will 
lead on to a precise and individualised management which will have better impact 
on the disease free survival and overall survival. 
Although different treatment modalities are available, Prevention is always better 
than cure. So the obstacle for affording the health facilities that commonly prevails 
among women in our country should be sought by creating awareness and 
implementing regular mammographic screening among all the women, with 
specific importance to, young women at risk for developing the breast cancer. With 
better awareness and screening the incidence and mortality rate of breast cancer 
can be reduced for which a coordinated effort is essential.  
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FIG 19: Invasive ductal carcinoma Grade III
differentiation. 
FIG 20: Malignant phylloides tumour of breast showing severe strom
and multiple mitoses. H & E x100 (3622/11)
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FIG 21: Malignant phylloides tumour of breast showing numerous mitotic 
figures
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FIG 27: ER and PR positive. x400 (1574/12).
 
 
 
 
 
FIG 28: ER positive, PR negative. x100 (1385 /12).
FIG 29: ER positive, PR negative. x400 (1385/12).
 
 
 
 
 
FIG 30: ER, PR negative. x100 (2120/12).
FIG 31: Lobular Carcinoma showing ER Positivity with focal PR
 
 
x100 (4130/11). 
 
 
 Positivity. 
FIG 32: Mucinous c
FIG 33: Papillary carcinoma showing strong ER and PR positivity
arcinoma - ER Positive, PR Negative.
x100 (3899/10). 
(2893/10). 
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ANNEXURE I 
PROFORMA 
Name: 
Age:  
Sex: 
Unit:  
IP No:                                                                         
HPE No:  
Menopausal status: 
Clinical Diagnosis: 
Breast: Right / Left 
Specimen (Type of Mastectomy): 
Past History: Trucut or Lumpectomy done if any: 
Macroscopic Examination: 
Specimen Size: 
Skin and Nipple: 
Tumour Site (Quadrant involved):  
Tumour Size: 
Consistency:  
Tumour Margins: Circumscribed / Infiltrative 
Posterior Margin: 
Lymph node: 
Number: 
Size (Largest): 
Microscopic Examination: 
Histopathological Diagnosis: 
Skin: Free / Involved 
Nipple: Free / Involved 
Muscle: Free / Involved 
Posterior Surgical Margin: Free / Involved 
LYMPH NODES: 
Total No: 
No. of nodes involved: 
Other findings: 
Histological Grade: 
Hormone Receptor Study: 
ER status if done:  Positive / Negative 
PR status if done:  Positive / Negative 
ANNEXURE    II 
 
WHO CLASSIFICATION OF TUMOURS OF THE BREAST (2003): 
 Epithelial Tumours: 
 Invasive  Ductal carcinoma, Not otherwise specified      8500/3 
 Mixed type carcinoma 
 Pleomorphic carcinoma          8022/3 
 Carcinoma with osteoclastic giant cells     8035/3 
 Carcinoma with choriocarcinomatous features 
 Carcinoma with melanotic features 
 Invasive Lobular carcinoma        8520/3 
 Tubular Carcinoma        8211/3 
 Invasive Cribriform Carcinoma                                  8201/3 
 Medullary Carcinoma                                                   8510/3 
 Mucinous Carcinoma and other tumours with abundant mucin: 
Mucinous Carcinoma         8480/3 
          Cysadenocarcinoma and Columnar cell Mucinous Carcinoma  8480/3 
   Signet ring cell Carcinoma       8490/3 
 Neuroendocrine Tumours: 
Solid Neuroendocrine Carcinoma 
Atypical Carcinoid tumour       8249/3 
Small cell Carcinoma        8041/3 
            Large cell Neuroendocrine Carcinoma     8013/3 
 Invasive Papillary Carcinoma       8503/3 
 Invasive Micropapillary Carcinoma      8507/3 
 Apocrine Carcinoma        8401/3 
 Metaplastic Carcinomas       8575/3 
Pure epithelial Metaplastic Carcinomas     8575/3 
 Squamous cell Carcinoma       8070/3 
 Adenocarcinoma with spindle cell metaplasia    8572/3 
        Adenosquamous Carcinoma       8560/3 
         Mucoepidermoid Carcinoma       8430/3 
            Mixed epithelial / mesenchymal Carcinomas     8575/3 
 Lipid-rich Carcinoma         8314/3 
 Secretory Carcinoma        8502/3 
 Oncocytic Carcinoma        8290/3 
 Adenoid Cystic Carcinoma       8200/3 
 Acinic Cell Carcinoma       8550/3 
 Glycogen-rich clear cell Carcinoma      8315/3 
 Sebaceous Carcinoma        8410/3 
 Inflammatory Carcinoma       8530/3 
 Lobular Neoplasia 
 Lobular Carcinoma in situ       8520/2 
 Intraductal proliferative lesions: 
Ductal hyperplasia 
          Flat epithelial atypia 
     Atypical ductal hyperplasia 
      Ductal carcinoma in situ       8500/2 
 Microinvasive Carcinoma 
 
 Intraductal Papillary neoplasms: 
Central papilloma         8503/0 
            Peripheral papilloma        8503/0 
             Atypical papilloma 
 Intraductal papillary carcinoma      8503/2 
 Intracystic papillary carcinoma      8504/2 
 Adenomas: 
Tubular adenoma        8211/0 
Lactating adenoma        8204/0 
Apocrine adenoma        8401/0 
Pleomorphic adenoma       8940/0 
Ductal adenoma        8503/0 
 Myoepithelial lesions: 
Myoepitheliosis 
Adenomyoepithelial adenosis 
Adenomyoepithelioma       8983/0 
Malignant myoepithelioma       8982/3 
 Mesenchymal Tumours: 
Hemangioma         9120/0 
Angiomatosis 
Hemangiopericytoma        9150/1 
Pseudoangiomatous stromal hyperplasia 
Myofibroblastoma        8825/0 
Fibromatosis         8821/1 
Inflammatory myofibroblastic tumour     8825/1 
Lipoma         8850/0 
Agiolipoma         8861/0 
Granular cell tumour        9580/0 
Neurofibroma         9540/0 
Schwannoma         9560/0 
Angiasarcoma         9120/3 
Liposarcoma         8850/3 
Rhabdomyosarcoma        8900/3 
Osteosarcoma         9180/3 
Leiomyoma         8890/0 
Leiomyosarcoma        8890/3 
 Fibroepithelial Tumours: 
Fibroadenoma         9010/0 
Phyllides tumour        9020/1 
  Benign         9020/0 
  Borderline        9020/1 
  Malignant        9020/3 
Periductal stromal sarcoma, low grade     9020/3 
Mammary Hamartoma 
 Tumours of the nipple: 
Nipple adenoma        8506/0 
Syringomatous adenoma       8407/0 
Paget’s disease of the nipple       8540/3 
 Malignant Lymphoma: 
Diffuse large B-cell Lymphoma      9680/3 
Burkitt  Lymphoma        9687/3 
Extranodal marginal zone Lymphoma of MALT type    9699/3 
Follicular Lymphoma        9690/3 
 Metastatic tumours 
 Tumours of the male breast: 
Gynacomastia 
InvasiveCarcinoma        8500/3 
In situ Carcinoma        8500/2 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE – III 
 
H &E STAINING PROCEDURE 
1. Bring the sections to water. 
2. Stain with Harris’s hematoxylin for 15 minutes. 
3. Rinse in tap water. 
4. Differentiate in acid alcohol until only nuclei remain blue. 
5. Wash in tap water very briefly. 
6. Dip in ammonia water (for 10-20 seconds) saturated lithium carbonate until 
sections are bright blue. 
7. Wash in running tap water for 10-20 minutes. 
8. Stain with eosin for 2 minutes. 
9. Dehydrate in 95% alcohol. 
10. Dehydrate in Absolute alcohol. 
11. Clearing in Xylene – 2 changes. 
12. Mount in DPX mountant. 
 
 
 
Immunohistochemistry for Hormone receptor study 
Staining procedure: 
1. Rehydrate tissue slides. 
2. Antigen retrieval is performed by pressure cooker method. 
3. Rinse in buffer for 3 minutes. 
4. Apply Primary antibody and incubate for 1 hour. 
5. Rinse in buffer for 3 minutes. 
6. Apply anti-polyvalent HRP polymer and incubate for 30 minutes at room 
temperature. 
7. Rinse 3 minutes in buffer. 
8. Rinse in distilled water. 
9. Add 1 drop (40-50microlitre) of DAB chromogen concentrate to each one ml 
vial, mix by swirling, apply to slides and wait for 5 minutes. 
10. Rinse in distilled water. 
11. Apply DAB Chromogen/substrate mixture and incubate for 5 minutes. 
12. Rinse 3 times in buffer 
13. Apply hematoxylin stain and incubate for 5 minutes. 
14. Rinse 3 times in distilled water 
15. Take the sections to running water for bluing. 
16. Dehydrate, clear and mount. 
ANNEXURE IV 
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ABBREVIATIONS 
 
ICMR - Indian Council Of Medical Research 
PBCR    - Population Based Cancer Registry 
F                  - Female 
PrM  - Premenopausal 
PM  - Postmenopausal 
R  - Right 
L  - Left 
MRM  - Modified Radical Mastectomy 
SM  - Simple Mastectomy 
U/O  - Upper Outer 
L/O  - Lower Outer  
L/I  - Lower Inner  
SA  - Sub Areolar     
ALL  - All Quadrant 
N  - Normal 
P  - Puckered 
U  - Ulcerated 
Nod  - Nodular         
Ret  -       Retracted 
PG   - Proliferative Growth      
ALND   - Axillary lymph node dissection 
LN   - Lymph Node 
MET LN      - Lymph Node with Metastasis  
SBR    - Scarff Bloom Richardson 
ER                - Estrogen Receptor 
PR   - Progesterone Receptor 
DFS  - Disease Free Survival 
OS   - Overall Survival 
IDC  - Invasive Ductal Carcinoma  
IDC - NOS - Invasive Ductal Carcinoma, not otherwise specified 
IDC-PD       - Invasive Ductal Carcinoma with Paget's Disease 
IDC-FCD - Invasive Ductal Carcinoma With Fibrocystic Disease 
IDC-FA - Invasive Ductal Carcinoma With Fibroadenoma 
ILC  - Invasive Lobular Carcinoma 
MC  - Mucinous Carcinoma  
ICC  - Invasive Cribriform Carcinoma     
PC  - Papillary Carcinoma      
MIPC  - Micropapillary Carcinoma    
MEC  - Medullary Carcinoma       
MPC  - Metaplastic Carcinoma      
PT   - Phyllides Tumour 
CSP-M - Malignant Cystosarcoma Phylloides  
                                        
  
 
 
ANNEXURE VII 
 
ANTI – PLAGIARISM CERTIFICATE 
 
 
 
 
 
 
 
      HP Diagnosis
site Size(cm) Tumour
MET 
LN
1 VELAMMAL 50 F PM 1929/10 MRM R U/O 3.5X3X2 N _ FIRM 5 IDC 2 II
2 AMEENA BEEVI 55 F PM 1988/10 MRM L U/O 5X4X3 N P FIRM 5 IDC 1 II
3 AMIRTHAM 30 F PrM 2081/10 MRM L U/O 4x3x2 N _ FIRM 6 IDC 5 III
4 IRULAYEE 79 F PM 2108/10 MRM L SA 7x6x4.5 N _ FIRM 10 IDC 9 I
5 MUNIYAMMAL 31 F PrM 2120/10 MRM L U/O 2X2X1 N _ FIRM 8 IDC            _ I
6 LAXMI 50 F PM 2141/10 MRM R U/O 2x1.5x1 N _ FIRM 7 IDC            _ III
7 MARIAMMAL 43 f PrM 2161/10 MRM R U/I 3X2X1 N Nod FIRM 15 IDC 4 II
8 SHANMUGAVALLI 35 F PrM 2267/10 MRM L SA 3X2X1 N _ FIRM 4 IDC 2 II
9 ARUMUGATHAMMAL 60 f PM 2458/10 MRM L U/O 8X4X3 N _ FIRM 13 IDC 13 III
10 ANNAMMAL 45 F PrM 2476/10 MRM R SA 3x2x1.5 N _ FIRM 6 IDC 1 II
11 TAMILSELVI 47 F PrM 2710/10 MRM L U/O 9X8X3 N _ FIRM 9 IDC 2 III
12 KATHAYEE 45 F PrM 2714/10 MRM L U/O 4X3X2 N _ FIRM 5 IDC 1 II
13 VALLIAMAL 65 F PM 2765/10 MRM R SA 6X5X3 U U FIRM 3 IDC 2 II
14 UNNAMALAI 57 F PM 2767/10 MRM L U/I 6X4X2 N _ FIRM 6 IDC 4 II
15 THANGAMMAL 43 F PrM 2772/10 MRM R L/I 10X9X4 N FIRM _ CSP-M            _ _
16 SUMATHY 24 F PrM 2832/10 MRM L U/O 10X8X3 N _ FIRM 6 IDC 5 III
17 THANGATHAI 70 F PM 2893/10 MRM R L/I 5X4X3 N _ FIRM 7 PC 6 _
18 MURUGESWARI 61 F PM 2934/10 MRM L U/O 4X3X2 N _ FIRM 6 IDC 2 II
19 SEETHALAXMI 38 F PrM 3041/10 MRM L U/I 12x8x3 N _ FIRM 9 IDC 4 III
20 ABIRAMI 38 F PrM 3060/10 MRM L U/O 4x3x2.5 N _ FIRM 20 IDC 20 II
21 JOTHI 70 F PM 3181/10 MRM R SA 2X2X1 N _ FIRM 7 IDC            _ I
22 PREMA 54 F PM    3487/10 MRM L U/O 6x5x5 N _ FIRM 5 IDC-PD 3 II
23 PASUPATHY 40 F PrM    3561/10 MRM L SA 4x3.5x3 N _ FIRM 14 IDC 11 III
24 SAMSATH 47 F PrM    3570/10 MRM R U/O 6x4x4 Ret U FIRM 7 IDC 6 II
25 LAXMI 50 F PM    3618/10 MRM R U/O 3.5x3x2 N _ FIRM 8 IDC 5 II
26 LAXMI 68 F PM    3620/10 MRM R L/O 3x2x2 N _ FIRM 7 IDC 5 II
27 JAYANTHI 45 F PrM    3661/10 MRM L SA 5x4x2 N _ FIRM 7 IDC 7 II
28 SHANTHADEVI 58 F PM    3663/10 MRM L U/O 2X2X1 N _ FIRM 3 IDC            _ I
29 ANDAL 48 F PrM    3727/10 MRM L U/I 6x5x4 N _ FIRM 4 IDC 4 III
30 ANGAMMAL 40 F PrM    3766/10 MRM L U/O 5x3x2 N P FIRM 2 IDC 2 II
31 RAMALAXMI 40 F PrM    3781/10 MRM L U/O 3x3x2 N _ FIRM 4 IDC 1 II
32 VASANTHA 47 F PrM    3877/10 MRM L L/O 5x4x3 N _ FIRM 5 IDC 1 II
Histolo-
gical 
Grade
ANNEXURE - V
MASTER CHART
LN(no)Specimen side
Tumour
Nipple Skin ConsistencyS.No Name Age Sex Menopause HPE NO
33 PAPPU 45 F PrM    3881/10 MRM R U/O 5x4x3 N P FIRM 6 IDC 6 III
34 PANDIAMMAL 42 F PrM    3886/10 MRM L SA 7.5x5x3 N _ FIRM 6 IDC 6 III
35 LAXMI 45 F PrM    3889/10 MRM L U/O 5x3x2 N _ FIRM 3 IDC 1 II
36 MUNIYAMMAL 55 F PM    3899/10 MRM L U/I 5x4x3 N P gelatinous 6 MC 2 _
37 DHAVAMANI 60 F PM 114/11 MRM L L/O 7X5X3 N P FIRM 4 IDC 4 III
38 ANGAMMAL 77 F PM 147/11 MRM R U/O 6X6X5 U PG FIRM 3 IDC-PD 2 III
39 SHAKILABEGUM 43 F PrM 224/11 MRM L U/O,U/I 9X8X5.5 N _ FIRM 5 IDC 5 III
40 MEERA 57 F PM 255/11 MRM R U/O 2X2X1 N _ FIRM 3 IDC             _ I
41 NACHAMMAL 40 F PrM 265/11 MRM R SA 6X5X3 R _ FIRM 9 IDC 3 II
42 MALLIKA 50 F PM  280/11 MRM R U/O 2X2X1 N _ FIRM 5 IDC             _ I
43 SAROJA 78 F PM 373/11 MRM R U/O 9x4x2.5 N _ FIRM 9 IDC 2 II
44 MAHALAXMI 40 F PrM 517/11 MRM R SA 2X2X1 N _ FIRM 4 IDC             _ I
45 RAJAMMAL 50 F PM 627/11 MRM R U/I 5X4X4 N _ gelatinous 7 MC 1 _
46 LAX,MI 45 F PrM 669/11 MRM L U/O 4X3X2 N _ FIRM 3 IDC 2 II
47 DEVI 45 F PrM 709/11 MRM L U/O,U/I 9x8x4 N _ FIRM 9 IDC 8 III
48 POOMADEVI 61 F PM 737/11 MRM R U/O 2X2X1 N _ FIRM 3 IDC             _ I
49 JEYA 45 F PrM 849/11 MRM L L/O 2X2X1 N _ FIRM 6 IDC             _ II
50 AATHILAXMI 35 F PrM 885/11 MRM R L/O 4.5x2.5x2 N _ FIRM 4 IDC 2 I
51 RAJALAXMI 55 F PM 1030/11 MRM R U/O 5x3.5x3 N _ FIRM 4 IDC 2 II
52 PAPPAMMAL 64 F PM 1074/11 MRM R U/O 3x2x1 N _ FIRM 2 IDC 2 II
53 PADMA 45 F PrM 1075/11 MRM R U/O 7x4x2 Ret _ FIRM 5 IDC 5 III
54 FATHIMA BEEVI 69 F PM 1098/11 MRM L U/O 4x2.5x2 N _ FIRM 9 IDC 2 II
55 CHIBA 30 F PrM 1152/11 MRM L U/O,U/I 8x6x3 N _ FIRM 4 IDC 2 II
56 AMARAVATHY 42 F PrM 1257/11 MRM R U/O 10X7X4 Ret _ FIRM 16 IDC 10 III
57 ARAYEE 50 F PM 1258/11 MRM L U/O 6X3X2 N _ FIRM 5 IDC 5 III
58 MUTHURAKKU 40 F PrM 1284/11 MRM L SA 3x3x2 N _ FIRM 1 IDC-,FCD 1 II
59 RAJESWARI 53 F PM 1294/11 MRM L SA 5x3x2 Ret _ FIRM 5 IDC 4 III
60 ALEEMA BEEVI 42 F PrM 1389/11 MRM R U/O,SA 9x8x6 N _ FIRM 4 IDC 4 III
61 KASIAMMAL 70 F PM 1418/11 MRM R U/O 5x5x3.5 N Nod FIRM 8 IDC 6 III
62 MARIAMMAL 40 F PrM 1569/11 MRM L L/I 12X10X8 N Nod FIRM _ CSP-M            _ _
63 PANCHAVARNAM 30 F PrM 1664/11 MRM L U/I 2X2X1 N _ FIRM 6 IDC            _ I
64 KALYANI 37 F PrM 1680/11 MRM R U/O,SA 5.5X5X1.5 N _ FIRM 2 IDC 2 III
65 SABITHA 45 F PrM 1686/11 MRM L U/O 3X2X1 N _ FIRM 12 IDC 2 II
66 GNANASUNDARI 45 F PrM 1733/11 MRM R U/O 6x4.5x3 N _ FIRM 12 IDC 12 III
67 BANUMATHY 28 F PrM 1777/11 MRM L U/O,SA 4x3.5x1.5 N _ FIRM 5 IDC 1 II
68 PITCHAIAMMAL 55 F PM 1827/11 MRM L L/O 2X2X2 N _ FIRM 5 IDC            _ I
69 KALIAMMAL 60 F PM 1828/11 MRM L SA 4x3x1 N _ FIRM 3 IDC 3 II
70 ESWARI 41 F PrM 1996/11 MRM R U/O 9x5x1.5 N _ FIRM 1 IDC 1 II
71 PARANJOTHI 60 f PM 2012/11 MRM L U/O.SA 6x4x3.5 Ret _ FIRM 6 IDC 5 III
72 MARIAMMAL 49 F PrM 2125/11 MRM L U/O 1.5x1x1 N _ FIRM 10 IDC            _ I
73 KARPAGAVALLI 28 F PrM 2127/11 MRM L U/O 10x9x5 N _ FIRM 16 IDC 16 II
74 RANI 40 F PrM 2236/11 MRM L U/O 4x3x2 N U FIRM 5 IDC 3 III
75 MUTHULAXMI 29 F PrM 2237/11 MRM R U/O 7x4.5x2 N _ FIRM 4 IDC 4 III
76 ATHIJABEGUM 37 F PrM 2260/11 MRM L U/I 2X2X1 N _ FIRM 8 IDC            _ I
77 LATHAMANGESWARI 53 F PM 2273/11 MRM L SA 6x3.5x2 N _ FIRM 6 IDC 6 III
78 KALIMUTHU 50 F PM 2310/11 MRM R U/O 4.5x3.5x3 N _ FIRM 6 IDC 4 II
79 SHANTHI 35 F PrM 2311/11 MRM R SA 2.5x2x2 N _ FIRM 4 IDC 2 III
80 VELAMMAL 37 F PrM 2420/11 MRM R SA 4x3x2 N _ FIRM 9 IDC 8 III
81 LALITHA 30 F PrM 2440/11 MRM L L/O 4x3x2 N _ FIRM 8 IDC 8 II
82 GORIJAN 37 F PrM 2481/11 MRM L U/O,SA 4x3.5x3 N _ FIRM 12 IDC 3 II
83 RAJAMMAL 50 F PM 2551/11 MRM L L/O 5x2.5x2 N _ FIRM 7 IDC 3 II
84 ARUMUGAM 40 F PrM 2560/11 MRM L SA 8x5x2.5 N _ FIRM 8 IDC 3 II
85 MARIYAM BEEVI 55 F PM 2629/11 MRM L U/O 5x3.5x3 N _ FIRM 5 IDC 1 II
86 VIJAYALAXMI 43 F PrM 2633/11 MRM L L/O 3x2.5x2 N _ FIRM 8 IDC 1 II
87 MUTHU 43 F PrM 2660/11 MRM R U/O,SA 7x4.5x4 N _ FIRM 5 IDC 3 III
88 CHITTUPONNU 36 F PrM 2670/11 MRM B/L U/O 4x3x2,1.5 N _ FIRM 5(2,3) IDC           2,1 II
89 SAVITHRI 46 F PrM 2791/11 MRM L L/O,L/I 7.5x7x4 Ret U FIRM 11 IDC 3 II
90 MARIAMMAL 58 F PM 2831/11 MRM L U/O 3.5x3x2.5 N _ FIRM _ IDC            _ III
91 PONNAMMAL 63 F PM 2846/11 MRM L SA 4X3.5X2 Ret _ FIRM 4 IDC 2 II
92 RAMAYEE 55 F PM 2875/11 MRM R U/O,SA 5x4x3 N _ FIRM 7 IDC 5 III
93 LAXMI 30 F PrM 2891/11 MRM L U/I 2x1.5x1.5 Ret _ FIRM 10 IDC            _ I
94 SARASWATHY 62 F PM 2926/11 MRM L L/O 8x5x4 N P FIRM 7 IDC 7 III
95 PAPAMMAL 65 F PM 2929/11 MRM R U/O 3x3x2 N _ FIRM 8 IDC 5 II
96 SHANTHI 38 F PrM 2971/11 MRM L U/O,U/I 8x5x2 N _ FIRM 1 IDC 1 III
97 ALAGAMMAL 49 F PrM 3014/11 MRM R SA 7x5x4 N Nod FIRM 8 IDC-PD 8 II
98 NALLAMMAL 60 F PM 3015/11 MRM L U/O,U/I 7.5x7x5 N U FIRM 7 IDC-PD 5 III
99 KALA 48 F PrM 3028/11 MRM R U/O,U/I 10x8x5 N _ FIRM 4 IDC 4 II
100 MUTHAMMAL 40 F PrM 3089/11 MRM R U/O 2X2X1 N U FIRM 3 IDC            _ I
101 GOMATHIAMMAL 40 F PrM 3305/11 MRM L L/O 5X4X3 N _ FIRM 7 MPC 2 _
102 ARAYAMMAL 75 F PM 3307/11 MRM L SA 6X5X4 N _ FIRM 6 IDC 4 III
103 SHANTHI 38 F PrM 3329/11 MRM R L/I 4X3X2 N _ FIRM 3 IDC-FCD 2 II
104 MUNIYAMMAL 60 F PM 3330/11 MRM R L/O 5X4X3 N _ HARD 4 IDC 3 II
105 INDHRANI 55 F PM 3356/11 MRM L U/O 2X2X1 N _ FIRM 5 IDC            _ I
106 MUTHU 70 F PM 3373/11 MRM R SA 2X2X1 N _ FIRM 7 IDC            _ I
107 AMSALAXMI 69 F PM 3428/11 MRM R L/O 6X3.5X3 N P FIRM 2 IDC 1 II
108 PANDIAMMAL 43 F PrM 3460/11 MRM L L/I 10X8X5 N _ FIRM 6 IDC 6 III
109 BACKIYAM 70 F PM 3622/11 SM R U/I 12X9X8 N _ FIRM _ CSP-M            _ _
110 PAPPA 68 F PM 3813/11 MRM L SA 7X4X2.5 N _ HARD 4 IDC 2 III
111 DHANALAXMI 40 F PrM 4009/11 MRM L U/O 6X3X2 N _ FIRM 6 IDC-FCD 2 II
112 SHENBAGAVALLI 45 F PrM 4037/11 MRM R L/O 6X5X4 N _ FIRM 4 IDC 1 II
113 SUBBAMMAL 45 F PrM 4130/11 MRM L L/O 6X5.5X5 N P FIRM 8 ILC 5 _
114 KALIMUTHU 70 F PM 4316/11 RM L L/O 2X2X1 N P FIRM 2 IDC             _ I
115 AMSAVALLI 35 F PrM 4334/11 MRM L L/O 2X2X1 N _ FIRM 15 IDC            _ I
116 INDHRANI 60 F PM 4355/11 MRM L L/I 6X5.5X4 N _ FIRM 10 IDC 7 III
117 MUNIYAMMAL 65 F PM 4374/11 MRM L U/O 5X4X3 N _ FIRM 7 IDC 2 II
118 KAMALAM 62 F PM 4378/12 MRM R L/O 2X2X1 N _ FIRM 3 IDC            _ I
119 TAMILARASI 60 F PM 99/12 MRM L U/O 3.5X1.5X1 N P FIRM 11 IDC 2 II
120 KULANTHAI SAROJA 57 F PM 129/12 MRM L U/I 2X2X1 N _ FIRM 4 IDC            _ I
121 GANDHIMATHI 39 F PrM 166/12 MRM L L/O 4X3X1.5 N _ HARD 11 IDC-FA 8 II
122 PERIAMMAL 55 F PM 175/12 MRM L U/O 6.5X5X4 N _ HARD 10 IDC 4 III
123 VIJAYA 47 F PrM 177/12 MRM R U/I 2X2X1 N _ HARD 7 IDC            _ I
124 LAXMI 42 F PrM 217/12 MRM R U/O 5.5X5X4 N P HARD 24 IDC 24 III
125 ANGAMUTHU 70 F PM 320/12 MRM R SA 6X5X4 N P HARD 17 IDC 2 II
126 LOORDHUMARI 60 F PM 445/12 MRM L SA 6X4X2 N _ gelatinous 6 MC 2 _
127 MEENATCHI 70 F PM 543/12 MRM R L/I 5X3X2.5 Ret P FIRM 3 IDC 2 II
128 SUNDHARI 43 F PrM 569/12 MRM L U/O 4.5x4x3 N _ FIRM 11 IDC 2 II
129 AROKIAMMAL 55 F PM 597/12 MRM L U/O 3X2X1 N _ FIRM 11 IDC 11 II
130 AMUDHA 38 F PrM 744/12 MRM L L/O 15X7X6 N _ FIRM 4 IDC 2 III
131 SHANMUGAVALLI 48 F PrM 842/12 MRM R U/O 3.5X3X2 N P FIRM 7 IDC 3 II
132 MARIAMMAL 42 F PrM 872/12 MRM L L/I 6.5x6x4 N P FIRM 5 IDC 4 III
133 MURUGESWARI 35 F PrM 903/12 MRM R U/O 6.5X6X5 N _ FIRM 4 IDC 1 III
134 NEELA 60 F PM 925/12 MRM R U/I 5.5X4.5X4 Ret P FIRM 6 ICC 2 _
135 LAXMI 60 F PM 984/12 MRM R U/O 12X9X6 N _ FIRM 9 IDC 2 II
136 DHANALAXMI 64 F PM 994/12 MRM L SA 8X7X1.5 R P Firm 5 IDC 2 II
137 MARIAMMAL 47 F PrM 1125/12 MRM L L/I 8X5X2 N _ Firm 14 MEC 1 _
138 INDHRANI 55 f PM 1276/12 MRM R U/O 6x5x4 N _ Firm 9 IDC 4 III
139 NATCHAMMAL 47 F PrM 1277/12 MRM L U/I 4.5X4X3 N _ Hard 7 IDC 3 II
140 PREMA 39 F PrM 1366/12 MRM R U/I 2X1.5X1 N _ Hard 5 IDC            _ I
141 PANCHU 35 F PrM 1384/12 MRM R U/O 2X2X1 N _ Hard 9 IDC            _ I
142 KALIAMMAL 55 F PM 1385/12 MRM R U/I 8X7X5 N _ Firm 14 IDC 14 III
143 MARIASELVAM 50 F PM 1520/12 SM R U/I 7X6X5.5 U P Firm 1 IDC-PD 1 II
144 MANJULA 58 F PM 1574/12 MRM L L/O 2X1.5X1 N _ Firm 0 IDC            _ I
145 MALLIKA 57 F PM 1598/12 MRM R SA 3.5X3X2 N _ FIRM 6 IDC 1 II
146 BACKIYALAXMI 35 F PrM 1621/12 MRM R L/O 3X2X1 N _ Firm 16 IDC 5 II
147 RASATHI 47 F PrM 1891/12 MRM R U/I 4X3X2 U P Hard 2 IDC-PD 2 II
148 SUBBURATHINAM 60 F PM 2069/12 MRM L L/I 4X3.5X3 N _ Firm 2 IDC 2 II
149 ANNAKODI 40 F PrM 2102/12 MRM L U/O,U/I 6X5X3 N _ Firm 10 IDC 2 II
150 ARUMUGA M 45 F PrM 2117/12 MRM R U/O 5X4X2 N _ Firm 7 IDC 2 II
151 SAGUBARNISHA 35 F PrM 2120/12 MRM R SA 6x5x4.5 N _ FIRM 13 IDC 2 II
152 LAXMIKANTHAM 71 F PM 2156/12 MRM L L/O 3x3x2.5 N _ FIRM 3 MIPC 3 _
153 VEERAMMAL 50 F PM 2216/12 MRM L U/I 6X3X2.5 N _ FIRM 18 IDC 3 III
154 ANNAPOORNAM 57 F PM 2271/12 MRM R U/I 2X2X1 N _ FIRM 4 IDC            _ I
155 RANI 49 F PrM 2273/12 MRM R U/O 4.5X4X3 N _ gelatinous 5 MC            _ _
156 THANGAM 47 F PrM 2293/12 MRM L U/O 5X4.5X3 N _ FIRM 6 IDC 4 II
157 SHOBANA 49 F PrM 2314/12 MRM R U/I 3x2.5x2 N _ FIRM 9 IDC 1 II
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INTRODUCTION Breast cancer is a multifactorial disease which is having distinct biological
subtypes. They have a broad spectrum of clinical, pathologic and molecular characteristic resulting in
different prognosis and therapeutic applications. Therefore, every lump in the breast should be
considered as a malignant lesion until proved otherwise. As breast is one of the frequent sites which
is under the influence of hormones, major hormonal changes during adolescent period, child bearing
period and at the time of menopause will affect the mammary tissue. Breast cancer is one among the
frequently encountered malignancies in the world among females. There should be enough knowledge
about its...
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